{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "const slidesRaw = \n",
    "`---\n",
    "\n",
    "# Induced Pluripotent Stem Cells Generated from Patients with ALS Can Be Differentiated into Motor Neurons\n",
    "\n",
    "---\n",
    "\n",
    "**Speaker Notes:**\n",
    "\n",
    "Welcome everyone. Today, I will be presenting a paper titled \"Induced Pluripotent Stem Cells Generated from Patients with ALS Can Be Differentiated into Motor Neurons.\" This groundbreaking study was conducted by John T. Dimos and colleagues, published in 2008. The research bridges the fields of neurodegenerative disease and stem cell biology by exploring the potential of patient-specific induced pluripotent stem cells (iPS cells) in modeling Amyotrophic Lateral Sclerosis (ALS).\n",
    "\n",
    "---\n",
    "\n",
    "# Background: Understanding ALS\n",
    "\n",
    "- **Amyotrophic Lateral Sclerosis (ALS):**\n",
    "  - Progressive neurodegenerative disorder\n",
    "  - Loss of motor neurons in spinal cord and motor cortex\n",
    "  - Leads to muscle weakness, paralysis, and death\n",
    "- **Current Challenges:**\n",
    "  - Limited understanding of disease mechanisms\n",
    "  - Lack of effective treatments\n",
    "\n",
    "---\n",
    "\n",
    "**Speaker Notes:**\n",
    "\n",
    "To set the stage, let's first understand ALS. ALS is a devastating neurodegenerative disease characterized by the progressive loss of motor neurons—the nerve cells responsible for controlling voluntary muscles. Patients experience muscle weakness, which leads to paralysis and, ultimately, death. One of the main challenges in ALS research is the limited availability of human motor neurons for study, hindering our ability to understand the disease mechanisms and develop effective treatments.\n",
    "\n",
    "---\n",
    "\n",
    "# Background: Induced Pluripotent Stem Cells (iPS Cells)\n",
    "\n",
    "- **iPS Cells:**\n",
    "  - Somatic cells reprogrammed to pluripotent state\n",
    "  - Capable of differentiating into any cell type\n",
    "- **Significance:**\n",
    "  - Potential for patient-specific disease modeling\n",
    "  - Applications in drug discovery and regenerative medicine\n",
    "\n",
    "---\n",
    "\n",
    "**Speaker Notes:**\n",
    "\n",
    "Next, let's discuss induced pluripotent stem cells, or iPS cells. These are somatic cells, such as skin fibroblasts, that have been reprogrammed back into a pluripotent state by introducing specific transcription factors. iPS cells can differentiate into any cell type, offering immense potential for patient-specific disease modeling, drug discovery, and regenerative therapies. This technology allows researchers to generate disease-relevant cell types from patients, providing a new avenue to study conditions like ALS.\n",
    "\n",
    "---\n",
    "\n",
    "# Rationale for the Study\n",
    "\n",
    "- **Need for Human Motor Neurons:**\n",
    "  - Understanding ALS requires access to affected cell types\n",
    "- **Limitations of Previous Models:**\n",
    "  - Animal models may not fully recapitulate human disease\n",
    "- **Objective:**\n",
    "  - Generate patient-specific iPS cells from elderly ALS patients\n",
    "  - Differentiate iPS cells into motor neurons and glia\n",
    "\n",
    "---\n",
    "\n",
    "**Speaker Notes:**\n",
    "\n",
    "The rationale behind this study stems from the need for a robust supply of human motor neurons carrying ALS-associated genes. Previous models, such as animal studies, may not accurately reflect human disease pathology. Therefore, the authors aimed to generate iPS cells directly from ALS patients, even elderly ones with chronic disease, and then differentiate these cells into motor neurons and glia. This approach could facilitate a better understanding of ALS and contribute to therapeutic development.\n",
    "\n",
    "---\n",
    "\n",
    "# Central Question\n",
    "\n",
    "- **Can iPS Cells Be Generated from Elderly ALS Patients and Differentiated into Motor Neurons?**\n",
    "\n",
    "---\n",
    "\n",
    "**Speaker Notes:**\n",
    "\n",
    "The central question addressed by this paper is: Can iPS cells be generated from elderly patients with ALS and subsequently differentiated into motor neurons? This question is crucial because if successful, it would demonstrate the feasibility of creating patient-specific cellular models for ALS, paving the way for future research and therapeutic strategies.\n",
    "\n",
    "---\n",
    "\n",
    "# Experimental Approach Overview\n",
    "\n",
    "1. **Patient Selection and Fibroblast Isolation**\n",
    "2. **Reprogramming Fibroblasts to iPS Cells**\n",
    "3. **Characterization of iPS Cells**\n",
    "4. **Differentiation into Motor Neurons**\n",
    "5. **Analysis of Differentiated Cells**\n",
    "\n",
    "---\n",
    "\n",
    "**Speaker Notes:**\n",
    "\n",
    "The study's experimental approach involved several key steps. First, fibroblasts were isolated from skin biopsies of elderly ALS patients. These fibroblasts were then reprogrammed into iPS cells using defined transcription factors. The resulting iPS cells were characterized to confirm pluripotency. Next, the iPS cells were directed to differentiate into motor neurons. Finally, the differentiated cells were analyzed to assess their identity and functionality.\n",
    "\n",
    "---\n",
    "\n",
    "# Methods: Patient Selection\n",
    "\n",
    "- **Participants:**\n",
    "  - Two elderly female siblings (A29 and A30)\n",
    "  - Ages 82 and 89\n",
    "  - Both heterozygous for SOD1 L144F mutation\n",
    "- **Clinical Presentation:**\n",
    "  - A29: Diagnosed with ALS\n",
    "  - A30: Asymptomatic but signs of upper motor neuron disease\n",
    "\n",
    "---\n",
    "\n",
    "**Speaker Notes:**\n",
    "\n",
    "Under approved protocols, the researchers recruited two elderly sisters, referred to as patients A29 and A30, aged 82 and 89, respectively. Both carried the rare SOD1 L144F mutation associated with familial ALS. Patient A29 had clear clinical manifestations of ALS, while A30 was asymptomatic but exhibited signs of upper motor neuron disease upon examination. These patients provided an opportunity to study iPS cell generation from individuals with a lifetime of exposure to the disease-causing mutation.\n",
    "\n",
    "---\n",
    "\n",
    "# Methods: Fibroblast Reprogramming\n",
    "\n",
    "- **Fibroblast Culture:**\n",
    "  - Skin biopsies obtained and fibroblasts cultured\n",
    "- **Reprogramming Factors:**\n",
    "  - Retroviral transduction with KLF4, SOX2, OCT4, c-MYC\n",
    "- **Culture Conditions:**\n",
    "  - Cells placed on mouse embryonic fibroblast feeders\n",
    "  - Transitioned to embryonic stem cell medium\n",
    "\n",
    "---\n",
    "\n",
    "**Speaker Notes:**\n",
    "\n",
    "Fibroblasts were isolated from skin biopsies of the patients and cultured in vitro. The fibroblasts were then reprogrammed using retroviral vectors encoding four transcription factors: KLF4, SOX2, OCT4, and c-MYC. These factors are known to induce pluripotency. The transduced cells were cultured on a feeder layer of mouse embryonic fibroblasts in conditions supportive of embryonic stem cells to promote reprogramming.\n",
    "\n",
    "---\n",
    "\n",
    "# Methods: Characterization of iPS Cells\n",
    "\n",
    "- **Verification of Reprogramming:**\n",
    "  - Morphological assessment\n",
    "  - Alkaline phosphatase activity\n",
    "- **Genetic Analysis:**\n",
    "  - DNA fingerprinting for patient identity\n",
    "  - Sequencing for SOD1 mutation\n",
    "- **Pluripotency Markers:**\n",
    "  - Expression of SSEA-3, SSEA-4, TRA-1-60, TRA-1-81, NANOG\n",
    "- **Karyotyping:**\n",
    "  - Confirm normal chromosomal structure\n",
    "\n",
    "---\n",
    "\n",
    "**Speaker Notes:**\n",
    "\n",
    "To confirm successful reprogramming, the researchers performed several analyses. They assessed colony morphology and alkaline phosphatase activity, a marker of pluripotency. Genetic analysis, including DNA fingerprinting and sequencing, verified that the iPS cells matched the patient fibroblasts and carried the SOD1 mutation. The expression of pluripotency markers such as SSEA-3, SSEA-4, TRA-1-60, TRA-1-81, and NANOG was evaluated through immunostaining. Normal karyotypes confirmed the chromosomal integrity of the iPS cells.\n",
    "\n",
    "---\n",
    "\n",
    "# Results: Generation of iPS Cells\n",
    "\n",
    "- **Successful Reprogramming:**\n",
    "  - Established stable iPS cell lines from patient A29\n",
    "- **Patient Identity Confirmed:**\n",
    "  - DNA fingerprinting matched donor fibroblasts\n",
    "  - SOD1 mutation present in iPS cells\n",
    "- **Silencing of Retroviral Transgenes:**\n",
    "  - Endogenous pluripotency genes activated\n",
    "  - Partial silencing of viral transgenes\n",
    "\n",
    "---\n",
    "\n",
    "**Speaker Notes:**\n",
    "\n",
    "The researchers successfully generated iPS cell lines from patient A29. DNA fingerprinting confirmed that these iPS cells were genetically identical to the donor fibroblasts. Sequencing demonstrated that the iPS cells carried the SOD1 L144F mutation. Importantly, the iPS cells activated endogenous pluripotency genes, and retroviral transgenes were partially silenced, indicating successful reprogramming.\n",
    "\n",
    "---\n",
    "\n",
    "# Results: Characterization of iPS Cells\n",
    "\n",
    "- **Pluripotency Gene Expression:**\n",
    "  - REX1, FOXD3, TERT, NANOG, CRIPTO expressed\n",
    "- **Embryoid Body Formation:**\n",
    "  - iPS cells formed embryoid bodies in suspension culture\n",
    "- **Differentiation Potential:**\n",
    "  - Cells differentiated into all three germ layers:\n",
    "    - Ectoderm: β-tubulin III-positive neurons\n",
    "    - Mesoderm: Desmin-positive muscle cells\n",
    "    - Endoderm: α-fetoprotein-positive cells\n",
    "\n",
    "---\n",
    "\n",
    "**Speaker Notes:**\n",
    "\n",
    "Quantitative RT-PCR showed that the iPS cells expressed key pluripotency genes at levels comparable to human embryonic stem cells. When cultured in suspension, the iPS cells formed embryoid bodies, which is characteristic of pluripotent cells. Upon differentiation, the iPS cells gave rise to cell types representative of all three germ layers: ectodermal neurons, mesodermal muscle cells, and endodermal cells. This demonstrated the pluripotency and differentiation potential of the patient-specific iPS cells.\n",
    "\n",
    "---\n",
    "\n",
    "# Results: Differentiation into Motor Neurons\n",
    "\n",
    "- **Directed Differentiation Protocol:**\n",
    "  - Treatment with retinoic acid and sonic hedgehog agonist\n",
    "- **Motor Neuron Markers:**\n",
    "  - HB9, ISLET 1/2 expression confirmed\n",
    "  - Choline acetyltransferase (ChAT) expression\n",
    "- **Glial Cells:**\n",
    "  - Presence of GFAP and S100-positive glia\n",
    "\n",
    "---\n",
    "\n",
    "**Speaker Notes:**\n",
    "\n",
    "The iPS cells were directed to differentiate into motor neurons using a protocol involving retinoic acid and a sonic hedgehog agonist. Immunostaining revealed that differentiated cells expressed motor neuron-specific markers such as HB9 and ISLET 1/2. Additionally, a significant proportion of these cells expressed ChAT, an enzyme indicative of mature cholinergic neurons. The cultures also contained glial cells positive for GFAP and S100, which are important for studying ALS pathology.\n",
    "\n",
    "---\n",
    "\n",
    "# Discussion: Significance of Findings\n",
    "\n",
    "- **Demonstrated Feasibility:**\n",
    "  - First generation of iPS cells from elderly patients with chronic disease\n",
    "- **Patient-Specific Disease Modeling:**\n",
    "  - Potential to study ALS in relevant human cell types\n",
    "- **Advancement in Stem Cell Research:**\n",
    "  - Overcame previous technical obstacles in reprogramming\n",
    "\n",
    "---\n",
    "\n",
    "**Speaker Notes:**\n",
    "\n",
    "This study is significant because it demonstrates the feasibility of generating iPS cells from elderly patients with a chronic neurodegenerative disease. It provides a proof-of-concept that patient-specific iPS cells can be used to produce the cell types affected in ALS, namely motor neurons and glia. This advances stem cell research by overcoming previous technical hurdles and opens new avenues for disease modeling and therapeutic development.\n",
    "\n",
    "---\n",
    "\n",
    "# Discussion: Limitations and Challenges\n",
    "\n",
    "- **Retroviral Integration:**\n",
    "  - Potential genetic and insertional mutagenesis risks\n",
    "- **Partial Transgene Silencing:**\n",
    "  - Some viral transgenes remained active\n",
    "- **Functional Maturity:**\n",
    "  - Further studies needed to assess physiological functionality of neurons\n",
    "\n",
    "---\n",
    "\n",
    "**Speaker Notes:**\n",
    "\n",
    "Despite the promising results, there are limitations to consider. The use of retroviral vectors poses risks due to potential insertional mutagenesis. Not all retroviral transgenes were fully silenced, which could affect cell behavior. Additionally, while the cells expressed markers of motor neurons, further work is needed to confirm their functional maturity and suitability for disease modeling or therapeutic applications.\n",
    "\n",
    "---\n",
    "\n",
    "# Conclusion: Key Findings\n",
    "\n",
    "- **iPS Cells Generated from ALS Patients:**\n",
    "  - Successful reprogramming of fibroblasts from elderly ALS patients\n",
    "- **Differentiation into Relevant Cell Types:**\n",
    "  - iPS cells differentiated into motor neurons and glia\n",
    "- **Potential Applications:**\n",
    "  - Disease modeling\n",
    "  - Drug screening\n",
    "  - Foundations for cell replacement therapies\n",
    "\n",
    "---\n",
    "\n",
    "**Speaker Notes:**\n",
    "\n",
    "In conclusion, the study successfully generated patient-specific iPS cells from elderly individuals with ALS and differentiated them into motor neurons and glia. These findings have significant implications for ALS research, offering new tools for disease modeling and drug discovery. This work lays the groundwork for potential future therapies involving patient-specific cell replacement.\n",
    "\n",
    "---\n",
    "\n",
    "# Future Directions: Disease Modeling\n",
    "\n",
    "- **Modeling ALS Pathogenesis:**\n",
    "  - Study disease mechanisms in patient-derived neurons\n",
    "- **Genetic Studies:**\n",
    "  - Investigate effects of SOD1 mutation at cellular level\n",
    "- **Comparative Analysis:**\n",
    "  - Compare iPS-derived neurons from affected and unaffected individuals\n",
    "\n",
    "---\n",
    "\n",
    "**Speaker Notes:**\n",
    "\n",
    "Future research will focus on using these patient-specific iPS cells to model ALS pathogenesis. By studying neurons derived from patients carrying the SOD1 mutation, researchers can investigate how this genetic alteration affects cellular function. Comparative studies between neurons from affected and unaffected individuals could shed light on disease mechanisms and identify potential therapeutic targets.\n",
    "\n",
    "---\n",
    "\n",
    "# Future Directions: Drug Screening\n",
    "\n",
    "- **High-Throughput Screening:**\n",
    "  - Test compounds on patient-derived motor neurons\n",
    "- **Identify Therapeutic Agents:**\n",
    "  - Discover drugs that improve neuron survival or function\n",
    "- **Personalized Medicine:**\n",
    "  - Tailor treatments based on patient-specific cellular responses\n",
    "\n",
    "---\n",
    "\n",
    "**Speaker Notes:**\n",
    "\n",
    "Another future direction is utilizing patient-specific motor neurons for drug screening. High-throughput assays can test numerous compounds to identify those that enhance neuron survival or mitigate disease phenotypes. This approach holds promise for discovering new therapeutic agents and advancing personalized medicine by tailoring treatments to individual patients based on their cellular responses.\n",
    "\n",
    "---\n",
    "\n",
    "# Future Directions: Cell Replacement Therapies\n",
    "\n",
    "- **Regenerative Medicine Potential:**\n",
    "  - Develop strategies for replacing lost motor neurons\n",
    "- **Overcoming Current Limitations:**\n",
    "  - Address challenges with iPS cell safety and integration\n",
    "- **Long-Term Goals:**\n",
    "  - Translate findings into clinical applications for ALS patients\n",
    "\n",
    "---\n",
    "\n",
    "**Speaker Notes:**\n",
    "\n",
    "Lastly, the ultimate goal is to explore cell replacement therapies. Developing methods to safely transplant patient-specific motor neurons back into patients could potentially restore lost functions. Overcoming current limitations, such as ensuring the safety of iPS cells and their proper integration, is crucial. These efforts aim to translate laboratory findings into tangible clinical benefits for ALS patients in the future.\n",
    "\n",
    "---\n",
    "\n",
    "# Closing Remarks\n",
    "\n",
    "- **Transformative Impact:**\n",
    "  - Study represents a significant step in stem cell and ALS research\n",
    "- **Collaboration:**\n",
    "  - Highlights importance of interdisciplinary efforts\n",
    "- **Acknowledgements:**\n",
    "  - Credit to the researchers and participants who made the study possible\n",
    "\n",
    "---\n",
    "\n",
    "**Speaker Notes:**\n",
    "\n",
    "In closing, this study represents a transformative advancement in both stem cell technology and ALS research. It highlights the potential of patient-specific iPS cells to revolutionize our understanding and treatment of neurodegenerative diseases. The success of this research underscores the importance of collaboration across disciplines and institutions. We owe gratitude to the dedicated researchers and the patients who generously contributed to this landmark study.\n",
    "\n",
    "---\n",
    "\n",
    "# References\n",
    "\n",
    "- **Dimos, J.T., et al. (2008).** Induced Pluripotent Stem Cells Generated from Patients with ALS Can Be Differentiated into Motor Neurons. _Science_, 321(5893), 1218-1221.\n",
    "\n",
    "---\n",
    "\n",
    "**Speaker Notes:**\n",
    "\n",
    "For those interested in exploring this study further, I encourage you to read the full paper published in _Science_ by Dimos and colleagues in 2008. Thank you for your attention, and I'm happy to discuss any questions you may have.\n",
    "\n",
    "---\n",
    "\n",
    "# End of Presentation\n",
    "\n",
    "---\n",
    "\n",
    "**Speaker Notes:**\n",
    "\n",
    "Thank you all for your time and engagement during this presentation. The development of patient-specific iPS cells represents a promising frontier in understanding and treating ALS. I look forward to any feedback or discussion points you might have.`"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "const slideStructureSystemPrompt = \n",
    "`You are an expert at extracting information in a structured format slides.`\n",
    "\n",
    "const getSlideStructuredPrompt = (slide: string) =>\n",
    "`\n",
    "I need to extract the following information from this chunk of text:\n",
    "\\`\\`\\`\n",
    "${slide}\n",
    "\\`\\`\\`\n",
    "`"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Number of slides: 43\n",
      "First slide: \n",
      "Second slide: # Induced Pluripotent Stem Cells Generated from Patients with ALS Can Be Differentiated into Motor Neurons\n"
     ]
    }
   ],
   "source": [
    "// Split slidesRaw by '---' into an array\n",
    "const slides = slidesRaw.split('---').map(slide => slide.trim());\n",
    "\n",
    "// Log the number of slides for verification\n",
    "console.log(`Number of slides: ${slides.length}`);\n",
    "\n",
    "// Optionally, you can log the first few slides to check the content\n",
    "console.log('First slide:', slides[0]);\n",
    "console.log('Second slide:', slides[1]);\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "I need to extract the following information from this chunk of text:\n",
      "```\n",
      "\n",
      "```\n",
      "\n"
     ]
    }
   ],
   "source": [
    "console.log(getSlideStructuredPrompt(slides[0]))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Current directory: /Users/danielgeorge/Documents/work/random/hackathon/paper-to-lecture\n",
      "Environment files found:\n",
      "\n",
      "Loading file: .env\n",
      "The .env file contains content.\n",
      "Environment variables loaded successfully.\n"
     ]
    }
   ],
   "source": [
    "async function getEnvFiles() {\n",
    "  try {\n",
    "    const currentDir = Deno.cwd();\n",
    "    console.log('Current directory:', currentDir);\n",
    "    const envPath = '/Users/danielgeorge/Documents/work/random/hackathon/paper-to-lecture/experiments/.env';\n",
    "    const content = await Deno.readTextFile(envPath);\n",
    "    return [{ name: '.env', content }];\n",
    "  } catch (error) {\n",
    "    console.error('Error reading .env file:', error);\n",
    "    return [];\n",
    "  }\n",
    "}\n",
    "\n",
    "const envFiles = await getEnvFiles();\n",
    "console.log('Environment files found:');\n",
    "if (envFiles.length === 0) {\n",
    "  console.log('No .env file found.');\n",
    "} else {\n",
    "  const envFile = envFiles[0];\n",
    "  console.log(`\\nLoading file: ${envFile.name}`);\n",
    "  if (envFile.content.trim()) {\n",
    "    console.log('The .env file contains content.');\n",
    "  } else {\n",
    "    console.log('The .env file is empty.');\n",
    "  }\n",
    "  \n",
    "  // Load the environment variables\n",
    "  const envVars = envFile.content.split('\\n').reduce((acc, line) => {\n",
    "    const [key, value] = line.split('=');\n",
    "    if (key && value) {\n",
    "      acc[key.trim()] = value.trim();\n",
    "    }\n",
    "    return acc;\n",
    "  }, {});\n",
    "\n",
    "  // Set the environment variables\n",
    "  Object.entries(envVars).forEach(([key, value]) => {\n",
    "    Deno.env.set(key, value);\n",
    "  });\n",
    "\n",
    "  console.log('Environment variables loaded successfully.');\n",
    "}\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Processing slide:  \n",
      "Processing slide:  # Induced Pluripotent Stem Cells Generated from Patients with ALS Can Be Differentiated into Motor Neurons\n",
      "Processing slide:  **Speaker Notes:**\n",
      "\n",
      "Welcome everyone. Today, I will be presenting a paper titled \"Induced Pluripotent Stem Cells Generated from Patients with ALS Can Be Differentiated into Motor Neurons.\" This groundbreaking study was conducted by John T. Dimos and colleagues, published in 2008. The research bridges the fields of neurodegenerative disease and stem cell biology by exploring the potential of patient-specific induced pluripotent stem cells (iPS cells) in modeling Amyotrophic Lateral Sclerosis (ALS).\n",
      "Processing slide:  # Background: Understanding ALS\n",
      "\n",
      "- **Amyotrophic Lateral Sclerosis (ALS):**\n",
      "  - Progressive neurodegenerative disorder\n",
      "  - Loss of motor neurons in spinal cord and motor cortex\n",
      "  - Leads to muscle weakness, paralysis, and death\n",
      "- **Current Challenges:**\n",
      "  - Limited understanding of disease mechanisms\n",
      "  - Lack of effective treatments\n",
      "Processing slide:  **Speaker Notes:**\n",
      "\n",
      "To set the stage, let's first understand ALS. ALS is a devastating neurodegenerative disease characterized by the progressive loss of motor neurons—the nerve cells responsible for controlling voluntary muscles. Patients experience muscle weakness, which leads to paralysis and, ultimately, death. One of the main challenges in ALS research is the limited availability of human motor neurons for study, hindering our ability to understand the disease mechanisms and develop effective treatments.\n",
      "Processing slide:  # Background: Induced Pluripotent Stem Cells (iPS Cells)\n",
      "\n",
      "- **iPS Cells:**\n",
      "  - Somatic cells reprogrammed to pluripotent state\n",
      "  - Capable of differentiating into any cell type\n",
      "- **Significance:**\n",
      "  - Potential for patient-specific disease modeling\n",
      "  - Applications in drug discovery and regenerative medicine\n",
      "Processing slide:  **Speaker Notes:**\n",
      "\n",
      "Next, let's discuss induced pluripotent stem cells, or iPS cells. These are somatic cells, such as skin fibroblasts, that have been reprogrammed back into a pluripotent state by introducing specific transcription factors. iPS cells can differentiate into any cell type, offering immense potential for patient-specific disease modeling, drug discovery, and regenerative therapies. This technology allows researchers to generate disease-relevant cell types from patients, providing a new avenue to study conditions like ALS.\n",
      "Processing slide:  # Rationale for the Study\n",
      "\n",
      "- **Need for Human Motor Neurons:**\n",
      "  - Understanding ALS requires access to affected cell types\n",
      "- **Limitations of Previous Models:**\n",
      "  - Animal models may not fully recapitulate human disease\n",
      "- **Objective:**\n",
      "  - Generate patient-specific iPS cells from elderly ALS patients\n",
      "  - Differentiate iPS cells into motor neurons and glia\n",
      "Processing slide:  **Speaker Notes:**\n",
      "\n",
      "The rationale behind this study stems from the need for a robust supply of human motor neurons carrying ALS-associated genes. Previous models, such as animal studies, may not accurately reflect human disease pathology. Therefore, the authors aimed to generate iPS cells directly from ALS patients, even elderly ones with chronic disease, and then differentiate these cells into motor neurons and glia. This approach could facilitate a better understanding of ALS and contribute to therapeutic development.\n",
      "Processing slide:  # Central Question\n",
      "\n",
      "- **Can iPS Cells Be Generated from Elderly ALS Patients and Differentiated into Motor Neurons?**\n",
      "Processing slide:  **Speaker Notes:**\n",
      "\n",
      "The central question addressed by this paper is: Can iPS cells be generated from elderly patients with ALS and subsequently differentiated into motor neurons? This question is crucial because if successful, it would demonstrate the feasibility of creating patient-specific cellular models for ALS, paving the way for future research and therapeutic strategies.\n",
      "Processing slide:  # Experimental Approach Overview\n",
      "\n",
      "1. **Patient Selection and Fibroblast Isolation**\n",
      "2. **Reprogramming Fibroblasts to iPS Cells**\n",
      "3. **Characterization of iPS Cells**\n",
      "4. **Differentiation into Motor Neurons**\n",
      "5. **Analysis of Differentiated Cells**\n",
      "Processing slide:  **Speaker Notes:**\n",
      "\n",
      "The study's experimental approach involved several key steps. First, fibroblasts were isolated from skin biopsies of elderly ALS patients. These fibroblasts were then reprogrammed into iPS cells using defined transcription factors. The resulting iPS cells were characterized to confirm pluripotency. Next, the iPS cells were directed to differentiate into motor neurons. Finally, the differentiated cells were analyzed to assess their identity and functionality.\n",
      "Processing slide:  # Methods: Patient Selection\n",
      "\n",
      "- **Participants:**\n",
      "  - Two elderly female siblings (A29 and A30)\n",
      "  - Ages 82 and 89\n",
      "  - Both heterozygous for SOD1 L144F mutation\n",
      "- **Clinical Presentation:**\n",
      "  - A29: Diagnosed with ALS\n",
      "  - A30: Asymptomatic but signs of upper motor neuron disease\n",
      "Processing slide:  **Speaker Notes:**\n",
      "\n",
      "Under approved protocols, the researchers recruited two elderly sisters, referred to as patients A29 and A30, aged 82 and 89, respectively. Both carried the rare SOD1 L144F mutation associated with familial ALS. Patient A29 had clear clinical manifestations of ALS, while A30 was asymptomatic but exhibited signs of upper motor neuron disease upon examination. These patients provided an opportunity to study iPS cell generation from individuals with a lifetime of exposure to the disease-causing mutation.\n",
      "Processing slide:  # Methods: Fibroblast Reprogramming\n",
      "\n",
      "- **Fibroblast Culture:**\n",
      "  - Skin biopsies obtained and fibroblasts cultured\n",
      "- **Reprogramming Factors:**\n",
      "  - Retroviral transduction with KLF4, SOX2, OCT4, c-MYC\n",
      "- **Culture Conditions:**\n",
      "  - Cells placed on mouse embryonic fibroblast feeders\n",
      "  - Transitioned to embryonic stem cell medium\n",
      "Processing slide:  **Speaker Notes:**\n",
      "\n",
      "Fibroblasts were isolated from skin biopsies of the patients and cultured in vitro. The fibroblasts were then reprogrammed using retroviral vectors encoding four transcription factors: KLF4, SOX2, OCT4, and c-MYC. These factors are known to induce pluripotency. The transduced cells were cultured on a feeder layer of mouse embryonic fibroblasts in conditions supportive of embryonic stem cells to promote reprogramming.\n",
      "Processing slide:  # Methods: Characterization of iPS Cells\n",
      "\n",
      "- **Verification of Reprogramming:**\n",
      "  - Morphological assessment\n",
      "  - Alkaline phosphatase activity\n",
      "- **Genetic Analysis:**\n",
      "  - DNA fingerprinting for patient identity\n",
      "  - Sequencing for SOD1 mutation\n",
      "- **Pluripotency Markers:**\n",
      "  - Expression of SSEA-3, SSEA-4, TRA-1-60, TRA-1-81, NANOG\n",
      "- **Karyotyping:**\n",
      "  - Confirm normal chromosomal structure\n",
      "Processing slide:  **Speaker Notes:**\n",
      "\n",
      "To confirm successful reprogramming, the researchers performed several analyses. They assessed colony morphology and alkaline phosphatase activity, a marker of pluripotency. Genetic analysis, including DNA fingerprinting and sequencing, verified that the iPS cells matched the patient fibroblasts and carried the SOD1 mutation. The expression of pluripotency markers such as SSEA-3, SSEA-4, TRA-1-60, TRA-1-81, and NANOG was evaluated through immunostaining. Normal karyotypes confirmed the chromosomal integrity of the iPS cells.\n",
      "Processing slide:  # Results: Generation of iPS Cells\n",
      "\n",
      "- **Successful Reprogramming:**\n",
      "  - Established stable iPS cell lines from patient A29\n",
      "- **Patient Identity Confirmed:**\n",
      "  - DNA fingerprinting matched donor fibroblasts\n",
      "  - SOD1 mutation present in iPS cells\n",
      "- **Silencing of Retroviral Transgenes:**\n",
      "  - Endogenous pluripotency genes activated\n",
      "  - Partial silencing of viral transgenes\n",
      "Processing slide:  **Speaker Notes:**\n",
      "\n",
      "The researchers successfully generated iPS cell lines from patient A29. DNA fingerprinting confirmed that these iPS cells were genetically identical to the donor fibroblasts. Sequencing demonstrated that the iPS cells carried the SOD1 L144F mutation. Importantly, the iPS cells activated endogenous pluripotency genes, and retroviral transgenes were partially silenced, indicating successful reprogramming.\n",
      "Processing slide:  # Results: Characterization of iPS Cells\n",
      "\n",
      "- **Pluripotency Gene Expression:**\n",
      "  - REX1, FOXD3, TERT, NANOG, CRIPTO expressed\n",
      "- **Embryoid Body Formation:**\n",
      "  - iPS cells formed embryoid bodies in suspension culture\n",
      "- **Differentiation Potential:**\n",
      "  - Cells differentiated into all three germ layers:\n",
      "    - Ectoderm: β-tubulin III-positive neurons\n",
      "    - Mesoderm: Desmin-positive muscle cells\n",
      "    - Endoderm: α-fetoprotein-positive cells\n",
      "Processing slide:  **Speaker Notes:**\n",
      "\n",
      "Quantitative RT-PCR showed that the iPS cells expressed key pluripotency genes at levels comparable to human embryonic stem cells. When cultured in suspension, the iPS cells formed embryoid bodies, which is characteristic of pluripotent cells. Upon differentiation, the iPS cells gave rise to cell types representative of all three germ layers: ectodermal neurons, mesodermal muscle cells, and endodermal cells. This demonstrated the pluripotency and differentiation potential of the patient-specific iPS cells.\n",
      "Processing slide:  # Results: Differentiation into Motor Neurons\n",
      "\n",
      "- **Directed Differentiation Protocol:**\n",
      "  - Treatment with retinoic acid and sonic hedgehog agonist\n",
      "- **Motor Neuron Markers:**\n",
      "  - HB9, ISLET 1/2 expression confirmed\n",
      "  - Choline acetyltransferase (ChAT) expression\n",
      "- **Glial Cells:**\n",
      "  - Presence of GFAP and S100-positive glia\n",
      "Processing slide:  **Speaker Notes:**\n",
      "\n",
      "The iPS cells were directed to differentiate into motor neurons using a protocol involving retinoic acid and a sonic hedgehog agonist. Immunostaining revealed that differentiated cells expressed motor neuron-specific markers such as HB9 and ISLET 1/2. Additionally, a significant proportion of these cells expressed ChAT, an enzyme indicative of mature cholinergic neurons. The cultures also contained glial cells positive for GFAP and S100, which are important for studying ALS pathology.\n",
      "Processing slide:  # Discussion: Significance of Findings\n",
      "\n",
      "- **Demonstrated Feasibility:**\n",
      "  - First generation of iPS cells from elderly patients with chronic disease\n",
      "- **Patient-Specific Disease Modeling:**\n",
      "  - Potential to study ALS in relevant human cell types\n",
      "- **Advancement in Stem Cell Research:**\n",
      "  - Overcame previous technical obstacles in reprogramming\n",
      "Processing slide:  **Speaker Notes:**\n",
      "\n",
      "This study is significant because it demonstrates the feasibility of generating iPS cells from elderly patients with a chronic neurodegenerative disease. It provides a proof-of-concept that patient-specific iPS cells can be used to produce the cell types affected in ALS, namely motor neurons and glia. This advances stem cell research by overcoming previous technical hurdles and opens new avenues for disease modeling and therapeutic development.\n",
      "Processing slide:  # Discussion: Limitations and Challenges\n",
      "\n",
      "- **Retroviral Integration:**\n",
      "  - Potential genetic and insertional mutagenesis risks\n",
      "- **Partial Transgene Silencing:**\n",
      "  - Some viral transgenes remained active\n",
      "- **Functional Maturity:**\n",
      "  - Further studies needed to assess physiological functionality of neurons\n",
      "Processing slide:  **Speaker Notes:**\n",
      "\n",
      "Despite the promising results, there are limitations to consider. The use of retroviral vectors poses risks due to potential insertional mutagenesis. Not all retroviral transgenes were fully silenced, which could affect cell behavior. Additionally, while the cells expressed markers of motor neurons, further work is needed to confirm their functional maturity and suitability for disease modeling or therapeutic applications.\n",
      "Processing slide:  # Conclusion: Key Findings\n",
      "\n",
      "- **iPS Cells Generated from ALS Patients:**\n",
      "  - Successful reprogramming of fibroblasts from elderly ALS patients\n",
      "- **Differentiation into Relevant Cell Types:**\n",
      "  - iPS cells differentiated into motor neurons and glia\n",
      "- **Potential Applications:**\n",
      "  - Disease modeling\n",
      "  - Drug screening\n",
      "  - Foundations for cell replacement therapies\n",
      "Processing slide:  **Speaker Notes:**\n",
      "\n",
      "In conclusion, the study successfully generated patient-specific iPS cells from elderly individuals with ALS and differentiated them into motor neurons and glia. These findings have significant implications for ALS research, offering new tools for disease modeling and drug discovery. This work lays the groundwork for potential future therapies involving patient-specific cell replacement.\n",
      "Processing slide:  # Future Directions: Disease Modeling\n",
      "\n",
      "- **Modeling ALS Pathogenesis:**\n",
      "  - Study disease mechanisms in patient-derived neurons\n",
      "- **Genetic Studies:**\n",
      "  - Investigate effects of SOD1 mutation at cellular level\n",
      "- **Comparative Analysis:**\n",
      "  - Compare iPS-derived neurons from affected and unaffected individuals\n",
      "Processing slide:  **Speaker Notes:**\n",
      "\n",
      "Future research will focus on using these patient-specific iPS cells to model ALS pathogenesis. By studying neurons derived from patients carrying the SOD1 mutation, researchers can investigate how this genetic alteration affects cellular function. Comparative studies between neurons from affected and unaffected individuals could shed light on disease mechanisms and identify potential therapeutic targets.\n",
      "Processing slide:  # Future Directions: Drug Screening\n",
      "\n",
      "- **High-Throughput Screening:**\n",
      "  - Test compounds on patient-derived motor neurons\n",
      "- **Identify Therapeutic Agents:**\n",
      "  - Discover drugs that improve neuron survival or function\n",
      "- **Personalized Medicine:**\n",
      "  - Tailor treatments based on patient-specific cellular responses\n",
      "Processing slide:  **Speaker Notes:**\n",
      "\n",
      "Another future direction is utilizing patient-specific motor neurons for drug screening. High-throughput assays can test numerous compounds to identify those that enhance neuron survival or mitigate disease phenotypes. This approach holds promise for discovering new therapeutic agents and advancing personalized medicine by tailoring treatments to individual patients based on their cellular responses.\n",
      "Processing slide:  # Future Directions: Cell Replacement Therapies\n",
      "\n",
      "- **Regenerative Medicine Potential:**\n",
      "  - Develop strategies for replacing lost motor neurons\n",
      "- **Overcoming Current Limitations:**\n",
      "  - Address challenges with iPS cell safety and integration\n",
      "- **Long-Term Goals:**\n",
      "  - Translate findings into clinical applications for ALS patients\n",
      "Processing slide:  **Speaker Notes:**\n",
      "\n",
      "Lastly, the ultimate goal is to explore cell replacement therapies. Developing methods to safely transplant patient-specific motor neurons back into patients could potentially restore lost functions. Overcoming current limitations, such as ensuring the safety of iPS cells and their proper integration, is crucial. These efforts aim to translate laboratory findings into tangible clinical benefits for ALS patients in the future.\n",
      "Processing slide:  # Closing Remarks\n",
      "\n",
      "- **Transformative Impact:**\n",
      "  - Study represents a significant step in stem cell and ALS research\n",
      "- **Collaboration:**\n",
      "  - Highlights importance of interdisciplinary efforts\n",
      "- **Acknowledgements:**\n",
      "  - Credit to the researchers and participants who made the study possible\n",
      "Processing slide:  **Speaker Notes:**\n",
      "\n",
      "In closing, this study represents a transformative advancement in both stem cell technology and ALS research. It highlights the potential of patient-specific iPS cells to revolutionize our understanding and treatment of neurodegenerative diseases. The success of this research underscores the importance of collaboration across disciplines and institutions. We owe gratitude to the dedicated researchers and the patients who generously contributed to this landmark study.\n",
      "Processing slide:  # References\n",
      "\n",
      "- **Dimos, J.T., et al. (2008).** Induced Pluripotent Stem Cells Generated from Patients with ALS Can Be Differentiated into Motor Neurons. _Science_, 321(5893), 1218-1221.\n",
      "Processing slide:  **Speaker Notes:**\n",
      "\n",
      "For those interested in exploring this study further, I encourage you to read the full paper published in _Science_ by Dimos and colleagues in 2008. Thank you for your attention, and I'm happy to discuss any questions you may have.\n",
      "Processing slide:  # End of Presentation\n",
      "Processing slide:  **Speaker Notes:**\n",
      "\n",
      "Thank you all for your time and engagement during this presentation. The development of patient-specific iPS cells represents a promising frontier in understanding and treating ALS. I look forward to any feedback or discussion points you might have.\n",
      "Response:  {\n",
      "  title: \"Extracted Information\",\n",
      "  markdownContent: \"\",\n",
      "  speakerNotes: \"No text provided for extraction.\",\n",
      "  _meta: {\n",
      "    usage: {\n",
      "      prompt_tokens: 109,\n",
      "      completion_tokens: 20,\n",
      "      total_tokens: 129,\n",
      "      prompt_tokens_details: { cached_tokens: 0 },\n",
      "      completion_tokens_details: { reasoning_tokens: 0 }\n",
      "    }\n",
      "  }\n",
      "}\n",
      "Response:  {\n",
      "  title: \"Induced Pluripotent Stem Cells Generated from Patients with ALS Can Be Differentiated into Motor Neurons\",\n",
      "  markdownContent: \"\",\n",
      "  speakerNotes: \"\",\n",
      "  _meta: {\n",
      "    usage: {\n",
      "      prompt_tokens: 133,\n",
      "      completion_tokens: 34,\n",
      "      total_tokens: 167,\n",
      "      prompt_tokens_details: { cached_tokens: 0 },\n",
      "      completion_tokens_details: { reasoning_tokens: 0 }\n",
      "    }\n",
      "  }\n",
      "}\n",
      "Response:  {\n",
      "  title: \"End of Presentation\",\n",
      "  markdownContent: \"# End of Presentation\",\n",
      "  speakerNotes: \"Conclude the presentation by summarizing key points and thanking the audience for their time.\",\n",
      "  _meta: {\n",
      "    usage: {\n",
      "      prompt_tokens: 114,\n",
      "      completion_tokens: 36,\n",
      "      total_tokens: 150,\n",
      "      prompt_tokens_details: { cached_tokens: 0 },\n",
      "      completion_tokens_details: { reasoning_tokens: 0 }\n",
      "    }\n",
      "  }\n",
      "}\n",
      "Response:  {\n",
      "  title: \"Central Question\",\n",
      "  markdownContent: \"- **Can iPS Cells Be Generated from Elderly ALS Patients and Differentiated into Motor Neurons?**\",\n",
      "  speakerNotes: \"This slide presents the central question that drives the research. It focuses on the potential of generating induced pluripotent stem (iPS) cells from elderly patients suffering from Amyotrophic Lateral Sclerosis (ALS) and whether these cells can then be differentiated into motor neurons.\",\n",
      "  _meta: {\n",
      "    usage: {\n",
      "      prompt_tokens: 136,\n",
      "      completion_tokens: 92,\n",
      "      total_tokens: 228,\n",
      "      prompt_tokens_details: { cached_tokens: 0 },\n",
      "      completion_tokens_details: { reasoning_tokens: 0 }\n",
      "    }\n",
      "  }\n",
      "}\n",
      "Response:  {\n",
      "  title: \"Speaker Notes\",\n",
      "  markdownContent: \"For those interested in exploring this study further, I encourage you to read the full paper published in _Science_ by Dimos and colleagues in 2008. Thank you for your attention, and I'm happy to discuss any questions you may have.\",\n",
      "  speakerNotes: \"\",\n",
      "  _meta: {\n",
      "    usage: {\n",
      "      prompt_tokens: 163,\n",
      "      completion_tokens: 63,\n",
      "      total_tokens: 226,\n",
      "      prompt_tokens_details: { cached_tokens: 0 },\n",
      "      completion_tokens_details: { reasoning_tokens: 0 }\n",
      "    }\n",
      "  }\n",
      "}\n",
      "Response:  {\n",
      "  title: \"Closing Remarks\",\n",
      "  markdownContent: \"### Transformative Impact:\\n\" +\n",
      "    \"- Study represents a significant step in stem cell and ALS research\\n\" +\n",
      "    \"\\n\" +\n",
      "    \"### Collaboration:\\n\" +\n",
      "    \"- Highlights importance of interdisciplinary efforts\\n\" +\n",
      "    \"\\n\" +\n",
      "    \"### Acknowledgements:\\n\" +\n",
      "    \"- Credit to the researchers and participants who made the study possible\",\n",
      "  speakerNotes: \"In concluding our presentation, we want to emphasize the transformative impact of our study on stem cell and ALS research, the critical role of collaboration in our success, and acknowledge the contributions of all researchers and participants involved.\",\n",
      "  _meta: {\n",
      "    usage: {\n",
      "      prompt_tokens: 168,\n",
      "      completion_tokens: 106,\n",
      "      total_tokens: 274,\n",
      "      prompt_tokens_details: { cached_tokens: 0 },\n",
      "      completion_tokens_details: { reasoning_tokens: 0 }\n",
      "    }\n",
      "  }\n",
      "}\n",
      "Response:  {\n",
      "  title: \"Closing Remarks on Stem Cell Technology and ALS Research\",\n",
      "  markdownContent: \"In closing, this study represents a transformative advancement in both stem cell technology and ALS research. It highlights the potential of patient-specific iPS cells to revolutionize our understanding and treatment of neurodegenerative diseases. The success of this research underscores the importance of collaboration across disciplines and institutions. We owe gratitude to the dedicated researchers and the patients who generously contributed to this landmark study.\",\n",
      "  speakerNotes: \"In this slide, we emphasize the importance of the research findings, the collaborative efforts behind them, and express gratitude to those involved.\",\n",
      "  _meta: {\n",
      "    usage: {\n",
      "      prompt_tokens: 188,\n",
      "      completion_tokens: 120,\n",
      "      total_tokens: 308,\n",
      "      prompt_tokens_details: { cached_tokens: 0 },\n",
      "      completion_tokens_details: { reasoning_tokens: 0 }\n",
      "    }\n",
      "  }\n",
      "}\n",
      "Response:  {\n",
      "  title: \"Conclusion: Key Findings\",\n",
      "  markdownContent: \"- **iPS Cells Generated from ALS Patients:**\\n\" +\n",
      "    \"  - Successful reprogramming of fibroblasts from elderly ALS patients\\n\" +\n",
      "    \"- **Differentiation into Relevant Cell Types:**\\n\" +\n",
      "    \"  - iPS cells differentiated into motor neurons and glia\\n\" +\n",
      "    \"- **Potential Applications:**\\n\" +\n",
      "    \"  - Disease modeling\\n\" +\n",
      "    \"  - Drug screening\\n\" +\n",
      "    \"  - Foundations for cell replacement therapies\",\n",
      "  speakerNotes: \"This slide summarizes the key findings related to induced pluripotent stem (iPS) cells generated from ALS patients. It highlights the successful reprogramming process, the differentiation capabilities into motor neurons and glia, and the various potential applications such as disease modeling, drug screening, and foundational work for future cell replacement therapies.\",\n",
      "  _meta: {\n",
      "    usage: {\n",
      "      prompt_tokens: 189,\n",
      "      completion_tokens: 156,\n",
      "      total_tokens: 345,\n",
      "      prompt_tokens_details: { cached_tokens: 0 },\n",
      "      completion_tokens_details: { reasoning_tokens: 0 }\n",
      "    }\n",
      "  }\n",
      "}\n",
      "Response:  {\n",
      "  title: \"Central Question of the Paper\",\n",
      "  markdownContent: \"Can iPS cells be generated from elderly patients with ALS and subsequently differentiated into motor neurons? This question is crucial because if successful, it would demonstrate the feasibility of creating patient-specific cellular models for ALS, paving the way for future research and therapeutic strategies.\",\n",
      "  speakerNotes: \"Discuss the implications of generating iPS cells from elderly ALS patients and the potential advancements in research and therapy this could lead to.\",\n",
      "  _meta: {\n",
      "    usage: {\n",
      "      prompt_tokens: 173,\n",
      "      completion_tokens: 91,\n",
      "      total_tokens: 264,\n",
      "      prompt_tokens_details: { cached_tokens: 0 },\n",
      "      completion_tokens_details: { reasoning_tokens: 0 }\n",
      "    }\n",
      "  }\n",
      "}\n",
      "Response:  {\n",
      "  title: \"Background: Induced Pluripotent Stem Cells (iPS Cells)\",\n",
      "  markdownContent: \"## iPS Cells:\\n\" +\n",
      "    \"- Somatic cells reprogrammed to pluripotent state\\n\" +\n",
      "    \"- Capable of differentiating into any cell type\\n\" +\n",
      "    \"\\n\" +\n",
      "    \"## Significance:\\n\" +\n",
      "    \"- Potential for patient-specific disease modeling\\n\" +\n",
      "    \"- Applications in drug discovery and regenerative medicine\",\n",
      "  speakerNotes: \"This slide provides an overview of induced pluripotent stem cells, also known as iPS cells. We highlight their ability to be reprogrammed from somatic cells into a pluripotent state, which allows them to differentiate into any cell type. Additionally, we discuss the significance of iPS cells in the context of patient-specific disease modeling and their potential applications in drug discovery and regenerative medicine.\",\n",
      "  _meta: {\n",
      "    usage: {\n",
      "      prompt_tokens: 183,\n",
      "      completion_tokens: 158,\n",
      "      total_tokens: 341,\n",
      "      prompt_tokens_details: { cached_tokens: 0 },\n",
      "      completion_tokens_details: { reasoning_tokens: 0 }\n",
      "    }\n",
      "  }\n",
      "}\n",
      "Response:  {\n",
      "  title: \"Future Direction in Drug Screening\",\n",
      "  markdownContent: \"- Utilize patient-specific motor neurons for drug screening.\\n\" +\n",
      "    \"- Implement high-throughput assays to test numerous compounds.\\n\" +\n",
      "    \"- Identify compounds that enhance neuron survival or mitigate disease phenotypes.\\n\" +\n",
      "    \"- Potential for discovering new therapeutic agents.\\n\" +\n",
      "    \"- Advancing personalized medicine by tailoring treatments based on cellular responses.\",\n",
      "  speakerNotes: \"Another future direction is utilizing patient-specific motor neurons for drug screening. High-throughput assays can test numerous compounds to identify those that enhance neuron survival or mitigate disease phenotypes. This approach holds promise for discovering new therapeutic agents and advancing personalized medicine by tailoring treatments to individual patients based on their cellular responses.\",\n",
      "  _meta: {\n",
      "    usage: {\n",
      "      prompt_tokens: 173,\n",
      "      completion_tokens: 134,\n",
      "      total_tokens: 307,\n",
      "      prompt_tokens_details: { cached_tokens: 0 },\n",
      "      completion_tokens_details: { reasoning_tokens: 0 }\n",
      "    }\n",
      "  }\n",
      "}\n",
      "Response:  {\n",
      "  title: \"Limitations of Retroviral Vectors in Research\",\n",
      "  markdownContent: \"- Risks of insertional mutagenesis with retroviral vectors.\\n\" +\n",
      "    \"- Not all retroviral transgenes were fully silenced, potentially affecting cell behavior.\\n\" +\n",
      "    \"- While cells express markers of motor neurons, further work is required to confirm functional maturity.\\n\" +\n",
      "    \"- Additional research needed for suitability in disease modeling or therapeutic applications.\",\n",
      "  speakerNotes: \"Despite the promising results, there are limitations to consider. The use of retroviral vectors poses risks due to potential insertional mutagenesis. Not all retroviral transgenes were fully silenced, which could affect cell behavior. Additionally, while the cells expressed markers of motor neurons, further work is needed to confirm their functional maturity and suitability for disease modeling or therapeutic applications.\",\n",
      "  _meta: {\n",
      "    usage: {\n",
      "      prompt_tokens: 188,\n",
      "      completion_tokens: 158,\n",
      "      total_tokens: 346,\n",
      "      prompt_tokens_details: { cached_tokens: 0 },\n",
      "      completion_tokens_details: { reasoning_tokens: 0 }\n",
      "    }\n",
      "  }\n",
      "}\n",
      "Response:  {\n",
      "  title: \"Methods: Patient Selection\",\n",
      "  markdownContent: \"## Participants:\\n\" +\n",
      "    \"- Two elderly female siblings (A29 and A30)\\n\" +\n",
      "    \"- Ages 82 and 89\\n\" +\n",
      "    \"- Both heterozygous for SOD1 L144F mutation\\n\" +\n",
      "    \"\\n\" +\n",
      "    \"## Clinical Presentation:\\n\" +\n",
      "    \"- A29: Diagnosed with ALS\\n\" +\n",
      "    \"- A30: Asymptomatic but signs of upper motor neuron disease\",\n",
      "  speakerNotes: \"This slide outlines the methods used for patient selection in the study. It describes the participants involved, specifically two elderly female siblings, and provides details on their ages and genetic mutation status. Additionally, it presents the clinical presentation of each participant, highlighting their diagnoses and symptoms.\",\n",
      "  _meta: {\n",
      "    usage: {\n",
      "      prompt_tokens: 190,\n",
      "      completion_tokens: 138,\n",
      "      total_tokens: 328,\n",
      "      prompt_tokens_details: { cached_tokens: 0 },\n",
      "      completion_tokens_details: { reasoning_tokens: 0 }\n",
      "    }\n",
      "  }\n",
      "}\n",
      "Response:  {\n",
      "  title: \"Speaker Notes\",\n",
      "  markdownContent: \"Thank you all for your time and engagement during this presentation. The development of patient-specific iPS cells represents a promising frontier in understanding and treating ALS. I look forward to any feedback or discussion points you might have.\",\n",
      "  speakerNotes: \"Thank you all for your time and engagement during this presentation. The development of patient-specific iPS cells represents a promising frontier in understanding and treating ALS. I look forward to any feedback or discussion points you might have.\",\n",
      "  _meta: {\n",
      "    usage: {\n",
      "      prompt_tokens: 157,\n",
      "      completion_tokens: 99,\n",
      "      total_tokens: 256,\n",
      "      prompt_tokens_details: { cached_tokens: 0 },\n",
      "      completion_tokens_details: { reasoning_tokens: 0 }\n",
      "    }\n",
      "  }\n",
      "}\n",
      "Response:  {\n",
      "  title: \"Future Directions: Drug Screening\",\n",
      "  markdownContent: \"## High-Throughput Screening:\\n\" +\n",
      "    \"- Test compounds on patient-derived motor neurons\\n\" +\n",
      "    \"\\n\" +\n",
      "    \"## Identify Therapeutic Agents:\\n\" +\n",
      "    \"- Discover drugs that improve neuron survival or function\\n\" +\n",
      "    \"\\n\" +\n",
      "    \"## Personalized Medicine:\\n\" +\n",
      "    \"- Tailor treatments based on patient-specific cellular responses\",\n",
      "  speakerNotes: \"This slide focuses on the future directions in drug screening, highlighting three key areas: High-Throughput Screening, Identifying Therapeutic Agents, and Personalized Medicine. Each area emphasizes the importance of innovative approaches to enhance drug discovery and treatment strategies that are more effective and tailored to individual patient needs.\",\n",
      "  _meta: {\n",
      "    usage: {\n",
      "      prompt_tokens: 173,\n",
      "      completion_tokens: 126,\n",
      "      total_tokens: 299,\n",
      "      prompt_tokens_details: { cached_tokens: 0 },\n",
      "      completion_tokens_details: { reasoning_tokens: 0 }\n",
      "    }\n",
      "  }\n",
      "}\n",
      "Response:  {\n",
      "  title: \"Rationale for the Study\",\n",
      "  markdownContent: \"## Need for Human Motor Neurons:\\n\" +\n",
      "    \"- Understanding ALS requires access to affected cell types\\n\" +\n",
      "    \"\\n\" +\n",
      "    \"## Limitations of Previous Models:\\n\" +\n",
      "    \"- Animal models may not fully recapitulate human disease\\n\" +\n",
      "    \"\\n\" +\n",
      "    \"## Objective:\\n\" +\n",
      "    \"- Generate patient-specific iPS cells from elderly ALS patients\\n\" +\n",
      "    \"- Differentiate iPS cells into motor neurons and glia\",\n",
      "  speakerNotes: \"This slide discusses the rationale behind the study, emphasizing the necessity of human motor neurons for understanding amyotrophic lateral sclerosis (ALS), the shortcomings of previous animal models in mimicking the human condition, and the primary objective of generating patient-specific induced pluripotent stem (iPS) cells.\",\n",
      "  _meta: {\n",
      "    usage: {\n",
      "      prompt_tokens: 191,\n",
      "      completion_tokens: 144,\n",
      "      total_tokens: 335,\n",
      "      prompt_tokens_details: { cached_tokens: 0 },\n",
      "      completion_tokens_details: { reasoning_tokens: 0 }\n",
      "    }\n",
      "  }\n",
      "}\n",
      "Response:  {\n",
      "  title: \"Future Directions: Disease Modeling\",\n",
      "  markdownContent: \"## Modeling ALS Pathogenesis:\\n\" +\n",
      "    \"- Study disease mechanisms in patient-derived neurons\\n\" +\n",
      "    \"\\n\" +\n",
      "    \"## Genetic Studies:\\n\" +\n",
      "    \"- Investigate effects of SOD1 mutation at cellular level\\n\" +\n",
      "    \"\\n\" +\n",
      "    \"## Comparative Analysis:\\n\" +\n",
      "    \"- Compare iPS-derived neurons from affected and unaffected individuals\",\n",
      "  speakerNotes: \"In this slide, we outline the future directions in disease modeling, particularly for ALS. We highlight three major areas: First, we will focus on modeling ALS pathogenesis by studying disease mechanisms in patient-derived neurons. Second, for genetic studies, we will investigate the effects of the SOD1 mutation at the cellular level. Lastly, we will conduct a comparative analysis of iPS-derived neurons from both affected and unaffected individuals to better understand the disease.\",\n",
      "  _meta: {\n",
      "    usage: {\n",
      "      prompt_tokens: 176,\n",
      "      completion_tokens: 158,\n",
      "      total_tokens: 334,\n",
      "      prompt_tokens_details: { cached_tokens: 0 },\n",
      "      completion_tokens_details: { reasoning_tokens: 0 }\n",
      "    }\n",
      "  }\n",
      "}\n",
      "Response:  {\n",
      "  title: \"Experimental Approach of the Study\",\n",
      "  markdownContent: \"1. **Isolation of Fibroblasts**: Fibroblasts were isolated from skin biopsies of elderly ALS patients.\\n\" +\n",
      "    \"2. **Reprogramming**: These fibroblasts were reprogrammed into iPS cells using defined transcription factors.\\n\" +\n",
      "    \"3. **Characterization**: The resulting iPS cells were characterized to confirm pluripotency.\\n\" +\n",
      "    \"4. **Differentiation**: iPS cells were directed to differentiate into motor neurons.\\n\" +\n",
      "    \"5. **Analysis**: The differentiated cells were analyzed to assess their identity and functionality.\",\n",
      "  speakerNotes: \"This slide outlines the key steps involved in the experimental approach of the study, detailing how fibroblasts were isolated, reprogrammed, characterized, differentiated, and analyzed.\",\n",
      "  _meta: {\n",
      "    usage: {\n",
      "      prompt_tokens: 199,\n",
      "      completion_tokens: 162,\n",
      "      total_tokens: 361,\n",
      "      prompt_tokens_details: { cached_tokens: 0 },\n",
      "      completion_tokens_details: { reasoning_tokens: 0 }\n",
      "    }\n",
      "  }\n",
      "}\n",
      "Response:  {\n",
      "  title: \"Background: Understanding ALS\",\n",
      "  markdownContent: \"## Amyotrophic Lateral Sclerosis (ALS)\\n\" +\n",
      "    \"- Progressive neurodegenerative disorder\\n\" +\n",
      "    \"- Loss of motor neurons in spinal cord and motor cortex\\n\" +\n",
      "    \"- Leads to muscle weakness, paralysis, and death\\n\" +\n",
      "    \"\\n\" +\n",
      "    \"## Current Challenges\\n\" +\n",
      "    \"- Limited understanding of disease mechanisms\\n\" +\n",
      "    \"- Lack of effective treatments\",\n",
      "  speakerNotes: \"This slide presents an overview of Amyotrophic Lateral Sclerosis (ALS), emphasizing its definition as a progressive neurodegenerative disorder that results in the loss of motor neurons, ultimately leading to muscle weakness, paralysis, and death. Additionally, it highlights current challenges in the field, including the limited understanding of the disease mechanisms and the lack of effective treatments available.\",\n",
      "  _meta: {\n",
      "    usage: {\n",
      "      prompt_tokens: 182,\n",
      "      completion_tokens: 147,\n",
      "      total_tokens: 329,\n",
      "      prompt_tokens_details: { cached_tokens: 0 },\n",
      "      completion_tokens_details: { reasoning_tokens: 0 }\n",
      "    }\n",
      "  }\n",
      "}\n",
      "Response:  {\n",
      "  title: \"Discussion: Significance of Findings\",\n",
      "  markdownContent: \"## Key Findings\\n\" +\n",
      "    \"\\n\" +\n",
      "    \"- **Demonstrated Feasibility:**\\n\" +\n",
      "    \"  - First generation of iPS cells from elderly patients with chronic disease\\n\" +\n",
      "    \"- **Patient-Specific Disease Modeling:**\\n\" +\n",
      "    \"  - Potential to study ALS in relevant human cell types\\n\" +\n",
      "    \"- **Advancement in Stem Cell Research:**\\n\" +\n",
      "    \"  - Overcame previous technical obstacles in reprogramming\",\n",
      "  speakerNotes: \"This slide discusses the significance of our findings. We have demonstrated the feasibility of creating iPS cells from elderly patients, which is groundbreaking. Additionally, it offers a novel approach to modeling diseases, particularly ALS, using relevant human cell types. Lastly, the advancements made in stem cell research show how we have overcome several technical challenges, paving the way for future research.\",\n",
      "  _meta: {\n",
      "    usage: {\n",
      "      prompt_tokens: 185,\n",
      "      completion_tokens: 165,\n",
      "      total_tokens: 350,\n",
      "      prompt_tokens_details: { cached_tokens: 0 },\n",
      "      completion_tokens_details: { reasoning_tokens: 0 }\n",
      "    }\n",
      "  }\n",
      "}\n",
      "Response:  {\n",
      "  title: \"Experimental Approach Overview\",\n",
      "  markdownContent: \"## Steps in the Approach\\n\" +\n",
      "    \"\\n\" +\n",
      "    \"1. **Patient Selection and Fibroblast Isolation**\\n\" +\n",
      "    \"2. **Reprogramming Fibroblasts to iPS Cells**\\n\" +\n",
      "    \"3. **Characterization of iPS Cells**\\n\" +\n",
      "    \"4. **Differentiation into Motor Neurons**\\n\" +\n",
      "    \"5. **Analysis of Differentiated Cells**\",\n",
      "  speakerNotes: \"This slide outlines the experimental approach taken in our study. The process begins with selecting patients and isolating fibroblasts. Next, these fibroblasts are reprogrammed into induced pluripotent stem cells (iPSCs). After characterizing these iPSCs, we differentiate them into motor neurons and perform analysis on the differentiated cells.\",\n",
      "  _meta: {\n",
      "    usage: {\n",
      "      prompt_tokens: 171,\n",
      "      completion_tokens: 155,\n",
      "      total_tokens: 326,\n",
      "      prompt_tokens_details: { cached_tokens: 0 },\n",
      "      completion_tokens_details: { reasoning_tokens: 0 }\n",
      "    }\n",
      "  }\n",
      "}\n",
      "Response:  {\n",
      "  title: \"Conclusion\",\n",
      "  markdownContent: \"In conclusion, the study successfully generated patient-specific iPS cells from elderly individuals with ALS and differentiated them into motor neurons and glia. These findings have significant implications for ALS research, offering new tools for disease modeling and drug discovery. This work lays the groundwork for potential future therapies involving patient-specific cell replacement.\",\n",
      "  speakerNotes: \"In conclusion, the study successfully generated patient-specific iPS cells from elderly individuals with ALS and differentiated them into motor neurons and glia. These findings have significant implications for ALS research, offering new tools for disease modeling and drug discovery. This work lays the groundwork for potential future therapies involving patient-specific cell replacement.\",\n",
      "  _meta: {\n",
      "    usage: {\n",
      "      prompt_tokens: 175,\n",
      "      completion_tokens: 134,\n",
      "      total_tokens: 309,\n",
      "      prompt_tokens_details: { cached_tokens: 0 },\n",
      "      completion_tokens_details: { reasoning_tokens: 0 }\n",
      "    }\n",
      "  }\n",
      "}\n",
      "Response:  {\n",
      "  title: \"Results: Characterization of iPS Cells\",\n",
      "  markdownContent: \"## Results: Characterization of iPS Cells\\n\" +\n",
      "    \"\\n\" +\n",
      "    \"- **Pluripotency Gene Expression:**\\n\" +\n",
      "    \"  - REX1, FOXD3, TERT, NANOG, CRIPTO expressed\\n\" +\n",
      "    \"- **Embryoid Body Formation:**\\n\" +\n",
      "    \"  - iPS cells formed embryoid bodies in suspension culture\\n\" +\n",
      "    \"- **Differentiation Potential:**\\n\" +\n",
      "    \"  - Cells differentiated into all three germ layers:\\n\" +\n",
      "    \"    - Ectoderm: β-tubulin III-positive neurons\\n\" +\n",
      "    \"    - Mesoderm: Desmin-positive muscle cells\\n\" +\n",
      "    \"    - Endoderm: α-fetoprotein-positive cells\",\n",
      "  speakerNotes: \"This slide presents the results of characterizing induced pluripotent stem (iPS) cells. We assessed three main aspects: pluripotency gene expression, embryoid body formation, and differentiation potential into the three germ layers.\",\n",
      "  _meta: {\n",
      "    usage: {\n",
      "      prompt_tokens: 231,\n",
      "      completion_tokens: 191,\n",
      "      total_tokens: 422,\n",
      "      prompt_tokens_details: { cached_tokens: 0 },\n",
      "      completion_tokens_details: { reasoning_tokens: 0 }\n",
      "    }\n",
      "  }\n",
      "}\n",
      "Response:  {\n",
      "  title: \"Understanding ALS\",\n",
      "  markdownContent: \"**What is ALS?**\\n\" +\n",
      "    \"- A devastating neurodegenerative disease.\\n\" +\n",
      "    \"- Characterized by progressive loss of motor neurons.\\n\" +\n",
      "    \"- Affects voluntary muscle control.\\n\" +\n",
      "    \"\\n\" +\n",
      "    \"**Impact on Patients:**\\n\" +\n",
      "    \"- Patients experience muscle weakness.\\n\" +\n",
      "    \"- Leads to paralysis and ultimately death.\\n\" +\n",
      "    \"\\n\" +\n",
      "    \"**Research Challenges:**\\n\" +\n",
      "    \"- Limited availability of human motor neurons for study.\\n\" +\n",
      "    \"- Hinders understanding of disease mechanisms.\\n\" +\n",
      "    \"- Affects development of effective treatments.\",\n",
      "  speakerNotes: \"To set the stage, let's first understand ALS. ALS is a devastating neurodegenerative disease characterized by the progressive loss of motor neurons—the nerve cells responsible for controlling voluntary muscles. Patients experience muscle weakness, which leads to paralysis and, ultimately, death. One of the main challenges in ALS research is the limited availability of human motor neurons for study, hindering our ability to understand the disease mechanisms and develop effective treatments.\",\n",
      "  _meta: {\n",
      "    usage: {\n",
      "      prompt_tokens: 197,\n",
      "      completion_tokens: 191,\n",
      "      total_tokens: 388,\n",
      "      prompt_tokens_details: { cached_tokens: 0 },\n",
      "      completion_tokens_details: { reasoning_tokens: 0 }\n",
      "    }\n",
      "  }\n",
      "}\n",
      "Response:  {\n",
      "  title: \"References\",\n",
      "  markdownContent: \"- **Dimos, J.T., et al. (2008).** Induced Pluripotent Stem Cells Generated from Patients with ALS Can Be Differentiated into Motor Neurons. _Science_, 321(5893), 1218-1221.\",\n",
      "  speakerNotes: \"This slide includes a reference to a significant study by Dimos et al. that discusses the generation of induced pluripotent stem cells from ALS patients and their differentiation into motor neurons.\",\n",
      "  _meta: {\n",
      "    usage: {\n",
      "      prompt_tokens: 167,\n",
      "      completion_tokens: 103,\n",
      "      total_tokens: 270,\n",
      "      prompt_tokens_details: { cached_tokens: 0 },\n",
      "      completion_tokens_details: { reasoning_tokens: 0 }\n",
      "    }\n",
      "  }\n",
      "}\n",
      "Response:  {\n",
      "  title: \"Differentiation of iPS Cells into Motor Neurons\",\n",
      "  markdownContent: \"- iPS cells were directed to differentiate into motor neurons using:\\n\" +\n",
      "    \"  - Retinoic acid\\n\" +\n",
      "    \"  - Sonic hedgehog agonist\\n\" +\n",
      "    \"- Immunostaining results:\\n\" +\n",
      "    \"  - Differentiated cells expressed motor neuron-specific markers:\\n\" +\n",
      "    \"    - HB9\\n\" +\n",
      "    \"    - ISLET 1/2\\n\" +\n",
      "    \"  - Significant proportion expressed ChAT (indicative of mature cholinergic neurons)\\n\" +\n",
      "    \"- Cultures contained glial cells positive for:\\n\" +\n",
      "    \"  - GFAP\\n\" +\n",
      "    \"  - S100\\n\" +\n",
      "    \"\\n\" +\n",
      "    \"*Important for studying ALS pathology.*\",\n",
      "  speakerNotes: \"The iPS cells were directed to differentiate into motor neurons using a protocol involving retinoic acid and a sonic hedgehog agonist. Immunostaining revealed that differentiated cells expressed motor neuron-specific markers such as HB9 and ISLET 1/2. Additionally, a significant proportion of these cells expressed ChAT, an enzyme indicative of mature cholinergic neurons. The cultures also contained glial cells positive for GFAP and S100, which are important for studying ALS pathology.\",\n",
      "  _meta: {\n",
      "    usage: {\n",
      "      prompt_tokens: 211,\n",
      "      completion_tokens: 231,\n",
      "      total_tokens: 442,\n",
      "      prompt_tokens_details: { cached_tokens: 0 },\n",
      "      completion_tokens_details: { reasoning_tokens: 0 }\n",
      "    }\n",
      "  }\n",
      "}\n",
      "Response:  {\n",
      "  title: \"Future Research on ALS Pathogenesis\",\n",
      "  markdownContent: \"- Focus on patient-specific iPS cells to model ALS pathogenesis\\n\" +\n",
      "    \"- Study neurons derived from SOD1 mutation patients \\n\" +\n",
      "    \"- Investigate effects of genetic alteration on cellular function \\n\" +\n",
      "    \"- Comparative studies between affected and unaffected individuals \\n\" +\n",
      "    \"- Aim to understand disease mechanisms and identify therapeutic targets\",\n",
      "  speakerNotes: \"Future research will focus on using these patient-specific iPS cells to model ALS pathogenesis. By studying neurons derived from patients carrying the SOD1 mutation, researchers can investigate how this genetic alteration affects cellular function. Comparative studies between neurons from affected and unaffected individuals could shed light on disease mechanisms and identify potential therapeutic targets.\",\n",
      "  _meta: {\n",
      "    usage: {\n",
      "      prompt_tokens: 177,\n",
      "      completion_tokens: 139,\n",
      "      total_tokens: 316,\n",
      "      prompt_tokens_details: { cached_tokens: 0 },\n",
      "      completion_tokens_details: { reasoning_tokens: 0 }\n",
      "    }\n",
      "  }\n",
      "}\n",
      "Response:  {\n",
      "  title: \"Significance of the Study\",\n",
      "  markdownContent: \"This study demonstrates the feasibility of generating iPS cells from elderly patients with a chronic neurodegenerative disease. It provides a proof-of-concept that patient-specific iPS cells can be used to produce the cell types affected in ALS, namely motor neurons and glia. This advances stem cell research by overcoming previous technical hurdles and opens new avenues for disease modeling and therapeutic development.\",\n",
      "  speakerNotes: \"This study is significant because it demonstrates the feasibility of generating iPS cells from elderly patients with a chronic neurodegenerative disease. It provides a proof-of-concept that patient-specific iPS cells can be used to produce the cell types affected in ALS, namely motor neurons and glia. This advances stem cell research by overcoming previous technical hurdles and opens new avenues for disease modeling and therapeutic development.\",\n",
      "  _meta: {\n",
      "    usage: {\n",
      "      prompt_tokens: 192,\n",
      "      completion_tokens: 168,\n",
      "      total_tokens: 360,\n",
      "      prompt_tokens_details: { cached_tokens: 0 },\n",
      "      completion_tokens_details: { reasoning_tokens: 0 }\n",
      "    }\n",
      "  }\n",
      "}\n",
      "Response:  {\n",
      "  title: \"Study of ALS Patients with SOD1 L144F Mutation\",\n",
      "  markdownContent: \"## Summary of Patients\\n\" +\n",
      "    \"- **Patients**: A29 and A30 (sisters)\\n\" +\n",
      "    \"- **Ages**: 82 (A29), 89 (A30)\\n\" +\n",
      "    \"- **Mutation**: SOD1 L144F (associated with familial ALS)\\n\" +\n",
      "    \"\\n\" +\n",
      "    \"## Patient Conditions\\n\" +\n",
      "    \"- **Patient A29**: Clear clinical manifestations of ALS.\\n\" +\n",
      "    \"- **Patient A30**: Asymptomatic but shows signs of upper motor neuron disease upon examination.\\n\" +\n",
      "    \"\\n\" +\n",
      "    \"## Purpose of Study\\n\" +\n",
      "    \"To study iPS cell generation from individuals with a lifetime of exposure to the disease-causing mutation.\",\n",
      "  speakerNotes: \"Under approved protocols, the researchers recruited two elderly sisters, referred to as patients A29 and A30, aged 82 and 89, respectively. Both carried the rare SOD1 L144F mutation associated with familial ALS. Patient A29 had clear clinical manifestations of ALS, while A30 was asymptomatic but exhibited signs of upper motor neuron disease upon examination. These patients provided an opportunity to study iPS cell generation from individuals with a lifetime of exposure to the disease-causing mutation.\",\n",
      "  _meta: {\n",
      "    usage: {\n",
      "      prompt_tokens: 212,\n",
      "      completion_tokens: 245,\n",
      "      total_tokens: 457,\n",
      "      prompt_tokens_details: { cached_tokens: 0 },\n",
      "      completion_tokens_details: { reasoning_tokens: 0 }\n",
      "    }\n",
      "  }\n",
      "}\n",
      "Response:  {\n",
      "  title: \"iPS Cell Line Generation from Patient A29\",\n",
      "  markdownContent: \"The researchers successfully generated iPS cell lines from patient A29. DNA fingerprinting confirmed that these iPS cells were genetically identical to the donor fibroblasts. Sequencing demonstrated that the iPS cells carried the SOD1 L144F mutation. Importantly, the iPS cells activated endogenous pluripotency genes, and retroviral transgenes were partially silenced, indicating successful reprogramming.\",\n",
      "  speakerNotes: \"The research highlights the successful generation of iPS cells from patient A29, confirming their genetic identity with donor fibroblasts, the presence of a specific mutation, and evidence of successful reprogramming.\",\n",
      "  _meta: {\n",
      "    usage: {\n",
      "      prompt_tokens: 194,\n",
      "      completion_tokens: 140,\n",
      "      total_tokens: 334,\n",
      "      prompt_tokens_details: { cached_tokens: 0 },\n",
      "      completion_tokens_details: { reasoning_tokens: 0 }\n",
      "    }\n",
      "  }\n",
      "}\n",
      "Response:  {\n",
      "  title: \"Exploring Cell Replacement Therapies\",\n",
      "  markdownContent: \"- Ultimate goal: explore cell replacement therapies  \\n\" +\n",
      "    \"- Develop methods for safe transplantation of patient-specific motor neurons  \\n\" +\n",
      "    \"- Potentially restore lost functions  \\n\" +\n",
      "    \"- Overcome limitations:  \\n\" +\n",
      "    \"  - Ensure safety of iPS cells  \\n\" +\n",
      "    \"  - Ensure proper integration  \\n\" +\n",
      "    \"- Translate laboratory findings into clinical benefits for ALS patients\",\n",
      "  speakerNotes: \"Lastly, the ultimate goal is to explore cell replacement therapies. Developing methods to safely transplant patient-specific motor neurons back into patients could potentially restore lost functions. Overcoming current limitations, such as ensuring the safety of iPS cells and their proper integration, is crucial. These efforts aim to translate laboratory findings into tangible clinical benefits for ALS patients in the future.\",\n",
      "  _meta: {\n",
      "    usage: {\n",
      "      prompt_tokens: 184,\n",
      "      completion_tokens: 159,\n",
      "      total_tokens: 343,\n",
      "      prompt_tokens_details: { cached_tokens: 0 },\n",
      "      completion_tokens_details: { reasoning_tokens: 0 }\n",
      "    }\n",
      "  }\n",
      "}\n",
      "Response:  {\n",
      "  title: \"Study Rationale and Objectives\",\n",
      "  markdownContent: \"**Speaker Notes:**  \\n\" +\n",
      "    \"The rationale behind this study stems from the need for a robust supply of human motor neurons carrying ALS-associated genes. Previous models, such as animal studies, may not accurately reflect human disease pathology. Therefore, the authors aimed to generate iPS cells directly from ALS patients, even elderly ones with chronic disease, and then differentiate these cells into motor neurons and glia. This approach could facilitate a better understanding of ALS and contribute to therapeutic development.\",\n",
      "  speakerNotes: \"The rationale behind this study stems from the need for a robust supply of human motor neurons carrying ALS-associated genes. Previous models, such as animal studies, may not accurately reflect human disease pathology. Therefore, the authors aimed to generate iPS cells directly from ALS patients, even elderly ones with chronic disease, and then differentiate these cells into motor neurons and glia. This approach could facilitate a better understanding of ALS and contribute to therapeutic development.\",\n",
      "  _meta: {\n",
      "    usage: {\n",
      "      prompt_tokens: 201,\n",
      "      completion_tokens: 197,\n",
      "      total_tokens: 398,\n",
      "      prompt_tokens_details: { cached_tokens: 0 },\n",
      "      completion_tokens_details: { reasoning_tokens: 0 }\n",
      "    }\n",
      "  }\n",
      "}\n",
      "Response:  {\n",
      "  title: \"Methods: Fibroblast Reprogramming\",\n",
      "  markdownContent: \"## Fibroblast Culture:\\n\" +\n",
      "    \"- Skin biopsies obtained and fibroblasts cultured\\n\" +\n",
      "    \"\\n\" +\n",
      "    \"## Reprogramming Factors:\\n\" +\n",
      "    \"- Retroviral transduction with KLF4, SOX2, OCT4, c-MYC\\n\" +\n",
      "    \"\\n\" +\n",
      "    \"## Culture Conditions:\\n\" +\n",
      "    \"- Cells placed on mouse embryonic fibroblast feeders\\n\" +\n",
      "    \"- Transitioned to embryonic stem cell medium\",\n",
      "  speakerNotes: \"This slide outlines the methods used for fibroblast reprogramming. It details the process of fibroblast culture, the reprogramming factors utilized, and the specific culture conditions necessary for successful reprogramming.\",\n",
      "  _meta: {\n",
      "    usage: {\n",
      "      prompt_tokens: 198,\n",
      "      completion_tokens: 134,\n",
      "      total_tokens: 332,\n",
      "      prompt_tokens_details: { cached_tokens: 0 },\n",
      "      completion_tokens_details: { reasoning_tokens: 0 }\n",
      "    }\n",
      "  }\n",
      "}\n",
      "Response:  {\n",
      "  title: \"Results: Differentiation into Motor Neurons\",\n",
      "  markdownContent: \"## Results: Differentiation into Motor Neurons\\n\" +\n",
      "    \"\\n\" +\n",
      "    \"- **Directed Differentiation Protocol:**\\n\" +\n",
      "    \"  - Treatment with retinoic acid and sonic hedgehog agonist\\n\" +\n",
      "    \"- **Motor Neuron Markers:**\\n\" +\n",
      "    \"  - HB9, ISLET 1/2 expression confirmed\\n\" +\n",
      "    \"  - Choline acetyltransferase (ChAT) expression\\n\" +\n",
      "    \"- **Glial Cells:**\\n\" +\n",
      "    \"  - Presence of GFAP and S100-positive glia\",\n",
      "  speakerNotes: \"This slide presents the results of our experiment on differentiating cells into motor neurons. We employed a directed differentiation protocol using retinoic acid and sonic hedgehog agonist. The markers indicating successful differentiation include HB9 and ISLET 1/2, along with choline acetyltransferase (ChAT). Additionally, we observed the presence of glial cells marked by GFAP and S100.\",\n",
      "  _meta: {\n",
      "    usage: {\n",
      "      prompt_tokens: 202,\n",
      "      completion_tokens: 198,\n",
      "      total_tokens: 400,\n",
      "      prompt_tokens_details: { cached_tokens: 0 },\n",
      "      completion_tokens_details: { reasoning_tokens: 0 }\n",
      "    }\n",
      "  }\n",
      "}\n",
      "Response:  {\n",
      "  title: \"Induced Pluripotent Stem Cells (iPS Cells)\",\n",
      "  markdownContent: \"**Overview of iPS Cells**  \\n\" +\n",
      "    \"- iPS cells are somatic cells, such as skin fibroblasts.  \\n\" +\n",
      "    \"- They are reprogrammed back into a pluripotent state.  \\n\" +\n",
      "    \"- This is done by introducing specific transcription factors.  \\n\" +\n",
      "    \"- iPS cells can differentiate into any cell type.  \\n\" +\n",
      "    \"\\n\" +\n",
      "    \"**Applications of iPS Cells**  \\n\" +\n",
      "    \"- Immense potential for patient-specific disease modeling.  \\n\" +\n",
      "    \"- Valuable in drug discovery.  \\n\" +\n",
      "    \"- Important for regenerative therapies.  \\n\" +\n",
      "    \"- Allows generation of disease-relevant cell types from patients, aiding the study of conditions like ALS.\",\n",
      "  speakerNotes: \"Next, let's discuss induced pluripotent stem cells, or iPS cells. These are somatic cells, such as skin fibroblasts, that have been reprogrammed back into a pluripotent state by introducing specific transcription factors. iPS cells can differentiate into any cell type, offering immense potential for patient-specific disease modeling, drug discovery, and regenerative therapies. This technology allows researchers to generate disease-relevant cell types from patients, providing a new avenue to study conditions like ALS.\",\n",
      "  _meta: {\n",
      "    usage: {\n",
      "      prompt_tokens: 212,\n",
      "      completion_tokens: 257,\n",
      "      total_tokens: 469,\n",
      "      prompt_tokens_details: { cached_tokens: 0 },\n",
      "      completion_tokens_details: { reasoning_tokens: 0 }\n",
      "    }\n",
      "  }\n",
      "}\n",
      "Response:  {\n",
      "  title: \"Results: Generation of iPS Cells\",\n",
      "  markdownContent: \"- **Successful Reprogramming:**\\n\" +\n",
      "    \"  - Established stable iPS cell lines from patient A29\\n\" +\n",
      "    \"- **Patient Identity Confirmed:**\\n\" +\n",
      "    \"  - DNA fingerprinting matched donor fibroblasts\\n\" +\n",
      "    \"  - SOD1 mutation present in iPS cells\\n\" +\n",
      "    \"- **Silencing of Retroviral Transgenes:**\\n\" +\n",
      "    \"  - Endogenous pluripotency genes activated\\n\" +\n",
      "    \"  - Partial silencing of viral transgenes\",\n",
      "  speakerNotes: \"This slide presents the results of our study on the generation of induced pluripotent stem (iPS) cells. We achieved successful reprogramming, confirming the identity of the patient from whom these cells were derived. Additionally, we observed key changes in the expression of transgenes, reflecting the activation of endogenous pluripotency genes.\",\n",
      "  _meta: {\n",
      "    usage: {\n",
      "      prompt_tokens: 201,\n",
      "      completion_tokens: 170,\n",
      "      total_tokens: 371,\n",
      "      prompt_tokens_details: { cached_tokens: 0 },\n",
      "      completion_tokens_details: { reasoning_tokens: 0 }\n",
      "    }\n",
      "  }\n",
      "}\n",
      "Response:  {\n",
      "  title: \"Key Findings on iPS Cells\",\n",
      "  markdownContent: \"- Quantitative RT-PCR showed iPS cells express key pluripotency genes at levels comparable to human embryonic stem cells.\\n\" +\n",
      "    \"- When cultured in suspension, iPS cells formed embryoid bodies characteristic of pluripotent cells.\\n\" +\n",
      "    \"- Upon differentiation, iPS cells gave rise to cell types from all three germ layers:  \\n\" +\n",
      "    \"  - Ectodermal neurons  \\n\" +\n",
      "    \"  - Mesodermal muscle cells  \\n\" +\n",
      "    \"  - Endodermal cells\\n\" +\n",
      "    \"- This demonstrates the pluripotency and differentiation potential of patient-specific iPS cells.\",\n",
      "  speakerNotes: \"Quantitative RT-PCR showed that the iPS cells expressed key pluripotency genes at levels comparable to human embryonic stem cells. When cultured in suspension, the iPS cells formed embryoid bodies, which is characteristic of pluripotent cells. Upon differentiation, the iPS cells gave rise to cell types representative of all three germ layers: ectodermal neurons, mesodermal muscle cells, and endodermal cells. This demonstrated the pluripotency and differentiation potential of the patient-specific iPS cells.\",\n",
      "  _meta: {\n",
      "    usage: {\n",
      "      prompt_tokens: 219,\n",
      "      completion_tokens: 237,\n",
      "      total_tokens: 456,\n",
      "      prompt_tokens_details: { cached_tokens: 0 },\n",
      "      completion_tokens_details: { reasoning_tokens: 0 }\n",
      "    }\n",
      "  }\n",
      "}\n",
      "Response:  {\n",
      "  title: \"Isolation and Reprogramming of Fibroblasts\",\n",
      "  markdownContent: \"- Fibroblasts were isolated from skin biopsies of patients and cultured in vitro.\\n\" +\n",
      "    \"- Reprogramming was done using retroviral vectors encoding four transcription factors:\\n\" +\n",
      "    \"  - KLF4\\n\" +\n",
      "    \"  - SOX2\\n\" +\n",
      "    \"  - OCT4\\n\" +\n",
      "    \"  - c-MYC\\n\" +\n",
      "    \"- These factors are known to induce pluripotency.\\n\" +\n",
      "    \"- The transduced cells were cultured on a feeder layer of mouse embryonic fibroblasts in conditions supportive of embryonic stem cells to promote reprogramming.\",\n",
      "  speakerNotes: \"Fibroblasts were isolated from skin biopsies of the patients and cultured in vitro. The fibroblasts were then reprogrammed using retroviral vectors encoding four transcription factors: KLF4, SOX2, OCT4, and c-MYC. These factors are known to induce pluripotency. The transduced cells were cultured on a feeder layer of mouse embryonic fibroblasts in conditions supportive of embryonic stem cells to promote reprogramming.\",\n",
      "  _meta: {\n",
      "    usage: {\n",
      "      prompt_tokens: 207,\n",
      "      completion_tokens: 216,\n",
      "      total_tokens: 423,\n",
      "      prompt_tokens_details: { cached_tokens: 0 },\n",
      "      completion_tokens_details: { reasoning_tokens: 0 }\n",
      "    }\n",
      "  }\n",
      "}\n",
      "Response:  {\n",
      "  title: \"Future Directions: Cell Replacement Therapies\",\n",
      "  markdownContent: \"## Regenerative Medicine Potential:\\n\" +\n",
      "    \"- Develop strategies for replacing lost motor neurons\\n\" +\n",
      "    \"\\n\" +\n",
      "    \"## Overcoming Current Limitations:\\n\" +\n",
      "    \"- Address challenges with iPS cell safety and integration\\n\" +\n",
      "    \"\\n\" +\n",
      "    \"## Long-Term Goals:\\n\" +\n",
      "    \"- Translate findings into clinical applications for ALS patients\",\n",
      "  speakerNotes: \"This slide discusses the future directions in cell replacement therapies, particularly focusing on regenerative medicine. We highlight the potential to develop strategies for replacing lost motor neurons, the need to overcome current limitations related to induced pluripotent stem (iPS) cells, and the long-term goals of translating these findings into clinical applications for patients with ALS.\",\n",
      "  _meta: {\n",
      "    usage: {\n",
      "      prompt_tokens: 175,\n",
      "      completion_tokens: 137,\n",
      "      total_tokens: 312,\n",
      "      prompt_tokens_details: { cached_tokens: 0 },\n",
      "      completion_tokens_details: { reasoning_tokens: 0 }\n",
      "    }\n",
      "  }\n",
      "}\n",
      "Response:  {\n",
      "  title: \"Discussion: Limitations and Challenges\",\n",
      "  markdownContent: \"- **Retroviral Integration:**  \\n\" +\n",
      "    \"  - Potential genetic and insertional mutagenesis risks  \\n\" +\n",
      "    \"- **Partial Transgene Silencing:**  \\n\" +\n",
      "    \"  - Some viral transgenes remained active  \\n\" +\n",
      "    \"- **Functional Maturity:**  \\n\" +\n",
      "    \"  - Further studies needed to assess physiological functionality of neurons\",\n",
      "  speakerNotes: \"In this slide, we address the key limitations and challenges faced in our study. We highlight the risks associated with retroviral integration, particularly in relation to genetic and insertional mutagenesis. Additionally, we discuss the issue of partial transgene silencing, where some viral transgenes continue to remain active. Finally, we emphasize the need for further studies to assess the physiological functionality of the neurons, as determining functional maturity is crucial for the long-term implications of our research.\",\n",
      "  _meta: {\n",
      "    usage: {\n",
      "      prompt_tokens: 173,\n",
      "      completion_tokens: 177,\n",
      "      total_tokens: 350,\n",
      "      prompt_tokens_details: { cached_tokens: 0 },\n",
      "      completion_tokens_details: { reasoning_tokens: 0 }\n",
      "    }\n",
      "  }\n",
      "}\n",
      "Response:  {\n",
      "  title: \"Methods: Characterization of iPS Cells\",\n",
      "  markdownContent: \"## Verification of Reprogramming:\\n\" +\n",
      "    \"- Morphological assessment\\n\" +\n",
      "    \"- Alkaline phosphatase activity\\n\" +\n",
      "    \"\\n\" +\n",
      "    \"## Genetic Analysis:\\n\" +\n",
      "    \"- DNA fingerprinting for patient identity\\n\" +\n",
      "    \"- Sequencing for SOD1 mutation\\n\" +\n",
      "    \"\\n\" +\n",
      "    \"## Pluripotency Markers:\\n\" +\n",
      "    \"- Expression of SSEA-3, SSEA-4, TRA-1-60, TRA-1-81, NANOG\\n\" +\n",
      "    \"\\n\" +\n",
      "    \"## Karyotyping:\\n\" +\n",
      "    \"- Confirm normal chromosomal structure\",\n",
      "  speakerNotes: \"This slide outlines the methods used to characterize induced pluripotent stem cells (iPS cells). We start with the verification of reprogramming, focusing on morphological assessments and alkaline phosphatase activity. Next, we carry out genetic analysis, which includes DNA fingerprinting to confirm patient identity and sequencing to check for SOD1 mutations. We also look at the expression of pluripotency markers such as SSEA-3, SSEA-4, TRA-1-60, TRA-1-81, and NANOG. Finally, karyotyping is performed to ensure normal chromosomal structure.\",\n",
      "  _meta: {\n",
      "    usage: {\n",
      "      prompt_tokens: 224,\n",
      "      completion_tokens: 236,\n",
      "      total_tokens: 460,\n",
      "      prompt_tokens_details: { cached_tokens: 0 },\n",
      "      completion_tokens_details: { reasoning_tokens: 0 }\n",
      "    }\n",
      "  }\n",
      "}\n",
      "Response:  {\n",
      "  title: \"Induced Pluripotent Stem Cells and ALS\",\n",
      "  markdownContent: \"### Title of the Paper\\n\" +\n",
      "    '\"Induced Pluripotent Stem Cells Generated from Patients with ALS Can Be Differentiated into Motor Neurons.\"\\n' +\n",
      "    \"\\n\" +\n",
      "    \"### Authors\\n\" +\n",
      "    \"John T. Dimos and colleagues\\n\" +\n",
      "    \"\\n\" +\n",
      "    \"### Year of Publication\\n\" +\n",
      "    \"2008\\n\" +\n",
      "    \"\\n\" +\n",
      "    \"### Key Focus\\n\" +\n",
      "    \"- The study bridges neurodegenerative disease and stem cell biology.\\n\" +\n",
      "    \"- Explores the potential of patient-specific induced pluripotent stem cells (iPS cells) in modeling Amyotrophic Lateral Sclerosis (ALS).\",\n",
      "  speakerNotes: 'Welcome everyone. Today, I will be presenting a paper titled \"Induced Pluripotent Stem Cells Generated from Patients with ALS Can Be Differentiated into Motor Neurons.\" This groundbreaking study was conducted by John T. Dimos and colleagues, published in 2008. The research bridges the fields of neurodegenerative disease and stem cell biology by exploring the potential of patient-specific induced pluripotent stem cells (iPS cells) in modeling Amyotrophic Lateral Sclerosis (ALS).',\n",
      "  _meta: {\n",
      "    usage: {\n",
      "      prompt_tokens: 214,\n",
      "      completion_tokens: 225,\n",
      "      total_tokens: 439,\n",
      "      prompt_tokens_details: { cached_tokens: 0 },\n",
      "      completion_tokens_details: { reasoning_tokens: 0 }\n",
      "    }\n",
      "  }\n",
      "}\n",
      "Response:  {\n",
      "  title: \"Confirmation of Successful Reprogramming\",\n",
      "  markdownContent: \"- Researchers performed several analyses to confirm successful reprogramming.\\n\" +\n",
      "    \"- Assessed colony morphology and alkaline phosphatase activity (a marker of pluripotency).\\n\" +\n",
      "    \"- Genetic analysis (DNA fingerprinting and sequencing) verified iPS cells matched patient fibroblasts and carried the SOD1 mutation.\\n\" +\n",
      "    \"- Evaluated expression of pluripotency markers:\\n\" +\n",
      "    \"  - SSEA-3\\n\" +\n",
      "    \"  - SSEA-4\\n\" +\n",
      "    \"  - TRA-1-60\\n\" +\n",
      "    \"  - TRA-1-81\\n\" +\n",
      "    \"  - NANOG through immunostaining.\\n\" +\n",
      "    \"- Confirmed normal karyotypes to verify chromosomal integrity of iPS cells.\",\n",
      "  speakerNotes: \"To confirm successful reprogramming, the researchers performed several analyses. They assessed colony morphology and alkaline phosphatase activity, a marker of pluripotency. Genetic analysis, including DNA fingerprinting and sequencing, verified that the iPS cells matched the patient fibroblasts and carried the SOD1 mutation. The expression of pluripotency markers such as SSEA-3, SSEA-4, TRA-1-60, TRA-1-81, and NANOG was evaluated through immunostaining. Normal karyotypes confirmed the chromosomal integrity of the iPS cells.\",\n",
      "  _meta: {\n",
      "    usage: {\n",
      "      prompt_tokens: 231,\n",
      "      completion_tokens: 263,\n",
      "      total_tokens: 494,\n",
      "      prompt_tokens_details: { cached_tokens: 0 },\n",
      "      completion_tokens_details: { reasoning_tokens: 0 }\n",
      "    }\n",
      "  }\n",
      "}\n"
     ]
    }
   ],
   "source": [
    "import Instructor from \"npm:@instructor-ai/instructor\";\n",
    "import OpenAI from 'https://deno.land/x/openai@v4.68.1/mod.ts';\n",
    "import { z } from \"npm:zod\"\n",
    "\n",
    "const openai = new OpenAI({\n",
    "    apiKey: Deno.env.get('OPENAI_API_KEY')\n",
    "});\n",
    "\n",
    "const client = Instructor({\n",
    "   client: openai,\n",
    "   mode: \"FUNCTIONS\"\n",
    "})\n",
    "\n",
    "const SlideSchema = z.object({\n",
    "  title: z.string().describe(\"The title of the slide\"),\n",
    "  markdownContent: z.string().describe(\"The main content of the slide in markdown format\"),\n",
    "  speakerNotes: z.string().describe(\"Speaker notes for the slide\")\n",
    "})\n",
    "\n",
    "async function processSlide(slide) {\n",
    "  console.log(\"Processing slide: \", slide)\n",
    "  const response = await client.chat.completions.create({\n",
    "    model: 'gpt-4o-mini',\n",
    "    messages: [\n",
    "        {role: 'system', content: slideStructureSystemPrompt},\n",
    "        {role: 'user', content: getSlideStructuredPrompt(slide)}],\n",
    "    response_model: { \n",
    "      schema: SlideSchema, \n",
    "      name: \"Slide\"\n",
    "    }\n",
    "  });\n",
    "  console.log(\"Response: \", response)\n",
    "  return response\n",
    "}\n",
    "\n",
    "const processedSlides = await Promise.all(slides.map(processSlide));"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[\n",
      "  {\n",
      "    title: \"Extracted Information\",\n",
      "    markdownContent: \"\",\n",
      "    speakerNotes: \"No text provided for extraction.\",\n",
      "    _meta: {\n",
      "      usage: {\n",
      "        prompt_tokens: 109,\n",
      "        completion_tokens: 20,\n",
      "        total_tokens: 129,\n",
      "        prompt_tokens_details: { cached_tokens: 0 },\n",
      "        completion_tokens_details: { reasoning_tokens: 0 }\n",
      "      }\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    title: \"Induced Pluripotent Stem Cells Generated from Patients with ALS Can Be Differentiated into Motor Neurons\",\n",
      "    markdownContent: \"\",\n",
      "    speakerNotes: \"\",\n",
      "    _meta: {\n",
      "      usage: {\n",
      "        prompt_tokens: 133,\n",
      "        completion_tokens: 34,\n",
      "        total_tokens: 167,\n",
      "        prompt_tokens_details: { cached_tokens: 0 },\n",
      "        completion_tokens_details: { reasoning_tokens: 0 }\n",
      "      }\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    title: \"Induced Pluripotent Stem Cells and ALS\",\n",
      "    markdownContent: \"### Title of the Paper\\n\" +\n",
      "      '\"Induced Pluripotent Stem Cells Generated from Patients with ALS Can Be Differentiated into Motor Neurons.\"\\n' +\n",
      "      \"\\n\" +\n",
      "      \"### Authors\\n\" +\n",
      "      \"John T. Dimos and colleagues\\n\" +\n",
      "      \"\\n\" +\n",
      "      \"### Year of Publication\\n\" +\n",
      "      \"2008\\n\" +\n",
      "      \"\\n\" +\n",
      "      \"### Key Focus\\n\" +\n",
      "      \"- The study bridges neurodegenerative disease and stem cell biology.\\n\" +\n",
      "      \"- Explores the potential of patient-specific induced pluripotent stem cells (iPS cells) in modeling Amyotrophic Lateral Sclerosis (ALS).\",\n",
      "    speakerNotes: 'Welcome everyone. Today, I will be presenting a paper titled \"Induced Pluripotent Stem Cells Generated from Patients with ALS Can Be Differentiated into Motor Neurons.\" This groundbreaking study was conducted by John T. Dimos and colleagues, published in 2008. The research bridges the fields of neurodegenerative disease and stem cell biology by exploring the potential of patient-specific induced pluripotent stem cells (iPS cells) in modeling Amyotrophic Lateral Sclerosis (ALS).',\n",
      "    _meta: {\n",
      "      usage: {\n",
      "        prompt_tokens: 214,\n",
      "        completion_tokens: 225,\n",
      "        total_tokens: 439,\n",
      "        prompt_tokens_details: { cached_tokens: 0 },\n",
      "        completion_tokens_details: { reasoning_tokens: 0 }\n",
      "      }\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    title: \"Background: Understanding ALS\",\n",
      "    markdownContent: \"## Amyotrophic Lateral Sclerosis (ALS)\\n\" +\n",
      "      \"- Progressive neurodegenerative disorder\\n\" +\n",
      "      \"- Loss of motor neurons in spinal cord and motor cortex\\n\" +\n",
      "      \"- Leads to muscle weakness, paralysis, and death\\n\" +\n",
      "      \"\\n\" +\n",
      "      \"## Current Challenges\\n\" +\n",
      "      \"- Limited understanding of disease mechanisms\\n\" +\n",
      "      \"- Lack of effective treatments\",\n",
      "    speakerNotes: \"This slide presents an overview of Amyotrophic Lateral Sclerosis (ALS), emphasizing its definition as a progressive neurodegenerative disorder that results in the loss of motor neurons, ultimately leading to muscle weakness, paralysis, and death. Additionally, it highlights current challenges in the field, including the limited understanding of the disease mechanisms and the lack of effective treatments available.\",\n",
      "    _meta: {\n",
      "      usage: {\n",
      "        prompt_tokens: 182,\n",
      "        completion_tokens: 147,\n",
      "        total_tokens: 329,\n",
      "        prompt_tokens_details: { cached_tokens: 0 },\n",
      "        completion_tokens_details: { reasoning_tokens: 0 }\n",
      "      }\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    title: \"Understanding ALS\",\n",
      "    markdownContent: \"**What is ALS?**\\n\" +\n",
      "      \"- A devastating neurodegenerative disease.\\n\" +\n",
      "      \"- Characterized by progressive loss of motor neurons.\\n\" +\n",
      "      \"- Affects voluntary muscle control.\\n\" +\n",
      "      \"\\n\" +\n",
      "      \"**Impact on Patients:**\\n\" +\n",
      "      \"- Patients experience muscle weakness.\\n\" +\n",
      "      \"- Leads to paralysis and ultimately death.\\n\" +\n",
      "      \"\\n\" +\n",
      "      \"**Research Challenges:**\\n\" +\n",
      "      \"- Limited availability of human motor neurons for study.\\n\" +\n",
      "      \"- Hinders understanding of disease mechanisms.\\n\" +\n",
      "      \"- Affects development of effective treatments.\",\n",
      "    speakerNotes: \"To set the stage, let's first understand ALS. ALS is a devastating neurodegenerative disease characterized by the progressive loss of motor neurons—the nerve cells responsible for controlling voluntary muscles. Patients experience muscle weakness, which leads to paralysis and, ultimately, death. One of the main challenges in ALS research is the limited availability of human motor neurons for study, hindering our ability to understand the disease mechanisms and develop effective treatments.\",\n",
      "    _meta: {\n",
      "      usage: {\n",
      "        prompt_tokens: 197,\n",
      "        completion_tokens: 191,\n",
      "        total_tokens: 388,\n",
      "        prompt_tokens_details: { cached_tokens: 0 },\n",
      "        completion_tokens_details: { reasoning_tokens: 0 }\n",
      "      }\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    title: \"Background: Induced Pluripotent Stem Cells (iPS Cells)\",\n",
      "    markdownContent: \"## iPS Cells:\\n\" +\n",
      "      \"- Somatic cells reprogrammed to pluripotent state\\n\" +\n",
      "      \"- Capable of differentiating into any cell type\\n\" +\n",
      "      \"\\n\" +\n",
      "      \"## Significance:\\n\" +\n",
      "      \"- Potential for patient-specific disease modeling\\n\" +\n",
      "      \"- Applications in drug discovery and regenerative medicine\",\n",
      "    speakerNotes: \"This slide provides an overview of induced pluripotent stem cells, also known as iPS cells. We highlight their ability to be reprogrammed from somatic cells into a pluripotent state, which allows them to differentiate into any cell type. Additionally, we discuss the significance of iPS cells in the context of patient-specific disease modeling and their potential applications in drug discovery and regenerative medicine.\",\n",
      "    _meta: {\n",
      "      usage: {\n",
      "        prompt_tokens: 183,\n",
      "        completion_tokens: 158,\n",
      "        total_tokens: 341,\n",
      "        prompt_tokens_details: { cached_tokens: 0 },\n",
      "        completion_tokens_details: { reasoning_tokens: 0 }\n",
      "      }\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    title: \"Induced Pluripotent Stem Cells (iPS Cells)\",\n",
      "    markdownContent: \"**Overview of iPS Cells**  \\n\" +\n",
      "      \"- iPS cells are somatic cells, such as skin fibroblasts.  \\n\" +\n",
      "      \"- They are reprogrammed back into a pluripotent state.  \\n\" +\n",
      "      \"- This is done by introducing specific transcription factors.  \\n\" +\n",
      "      \"- iPS cells can differentiate into any cell type.  \\n\" +\n",
      "      \"\\n\" +\n",
      "      \"**Applications of iPS Cells**  \\n\" +\n",
      "      \"- Immense potential for patient-specific disease modeling.  \\n\" +\n",
      "      \"- Valuable in drug discovery.  \\n\" +\n",
      "      \"- Important for regenerative therapies.  \\n\" +\n",
      "      \"- Allows generation of disease-relevant cell types from patients, aiding the study of conditions like ALS.\",\n",
      "    speakerNotes: \"Next, let's discuss induced pluripotent stem cells, or iPS cells. These are somatic cells, such as skin fibroblasts, that have been reprogrammed back into a pluripotent state by introducing specific transcription factors. iPS cells can differentiate into any cell type, offering immense potential for patient-specific disease modeling, drug discovery, and regenerative therapies. This technology allows researchers to generate disease-relevant cell types from patients, providing a new avenue to study conditions like ALS.\",\n",
      "    _meta: {\n",
      "      usage: {\n",
      "        prompt_tokens: 212,\n",
      "        completion_tokens: 257,\n",
      "        total_tokens: 469,\n",
      "        prompt_tokens_details: { cached_tokens: 0 },\n",
      "        completion_tokens_details: { reasoning_tokens: 0 }\n",
      "      }\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    title: \"Rationale for the Study\",\n",
      "    markdownContent: \"## Need for Human Motor Neurons:\\n\" +\n",
      "      \"- Understanding ALS requires access to affected cell types\\n\" +\n",
      "      \"\\n\" +\n",
      "      \"## Limitations of Previous Models:\\n\" +\n",
      "      \"- Animal models may not fully recapitulate human disease\\n\" +\n",
      "      \"\\n\" +\n",
      "      \"## Objective:\\n\" +\n",
      "      \"- Generate patient-specific iPS cells from elderly ALS patients\\n\" +\n",
      "      \"- Differentiate iPS cells into motor neurons and glia\",\n",
      "    speakerNotes: \"This slide discusses the rationale behind the study, emphasizing the necessity of human motor neurons for understanding amyotrophic lateral sclerosis (ALS), the shortcomings of previous animal models in mimicking the human condition, and the primary objective of generating patient-specific induced pluripotent stem (iPS) cells.\",\n",
      "    _meta: {\n",
      "      usage: {\n",
      "        prompt_tokens: 191,\n",
      "        completion_tokens: 144,\n",
      "        total_tokens: 335,\n",
      "        prompt_tokens_details: { cached_tokens: 0 },\n",
      "        completion_tokens_details: { reasoning_tokens: 0 }\n",
      "      }\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    title: \"Study Rationale and Objectives\",\n",
      "    markdownContent: \"**Speaker Notes:**  \\n\" +\n",
      "      \"The rationale behind this study stems from the need for a robust supply of human motor neurons carrying ALS-associated genes. Previous models, such as animal studies, may not accurately reflect human disease pathology. Therefore, the authors aimed to generate iPS cells directly from ALS patients, even elderly ones with chronic disease, and then differentiate these cells into motor neurons and glia. This approach could facilitate a better understanding of ALS and contribute to therapeutic development.\",\n",
      "    speakerNotes: \"The rationale behind this study stems from the need for a robust supply of human motor neurons carrying ALS-associated genes. Previous models, such as animal studies, may not accurately reflect human disease pathology. Therefore, the authors aimed to generate iPS cells directly from ALS patients, even elderly ones with chronic disease, and then differentiate these cells into motor neurons and glia. This approach could facilitate a better understanding of ALS and contribute to therapeutic development.\",\n",
      "    _meta: {\n",
      "      usage: {\n",
      "        prompt_tokens: 201,\n",
      "        completion_tokens: 197,\n",
      "        total_tokens: 398,\n",
      "        prompt_tokens_details: { cached_tokens: 0 },\n",
      "        completion_tokens_details: { reasoning_tokens: 0 }\n",
      "      }\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    title: \"Central Question\",\n",
      "    markdownContent: \"- **Can iPS Cells Be Generated from Elderly ALS Patients and Differentiated into Motor Neurons?**\",\n",
      "    speakerNotes: \"This slide presents the central question that drives the research. It focuses on the potential of generating induced pluripotent stem (iPS) cells from elderly patients suffering from Amyotrophic Lateral Sclerosis (ALS) and whether these cells can then be differentiated into motor neurons.\",\n",
      "    _meta: {\n",
      "      usage: {\n",
      "        prompt_tokens: 136,\n",
      "        completion_tokens: 92,\n",
      "        total_tokens: 228,\n",
      "        prompt_tokens_details: { cached_tokens: 0 },\n",
      "        completion_tokens_details: { reasoning_tokens: 0 }\n",
      "      }\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    title: \"Central Question of the Paper\",\n",
      "    markdownContent: \"Can iPS cells be generated from elderly patients with ALS and subsequently differentiated into motor neurons? This question is crucial because if successful, it would demonstrate the feasibility of creating patient-specific cellular models for ALS, paving the way for future research and therapeutic strategies.\",\n",
      "    speakerNotes: \"Discuss the implications of generating iPS cells from elderly ALS patients and the potential advancements in research and therapy this could lead to.\",\n",
      "    _meta: {\n",
      "      usage: {\n",
      "        prompt_tokens: 173,\n",
      "        completion_tokens: 91,\n",
      "        total_tokens: 264,\n",
      "        prompt_tokens_details: { cached_tokens: 0 },\n",
      "        completion_tokens_details: { reasoning_tokens: 0 }\n",
      "      }\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    title: \"Experimental Approach Overview\",\n",
      "    markdownContent: \"## Steps in the Approach\\n\" +\n",
      "      \"\\n\" +\n",
      "      \"1. **Patient Selection and Fibroblast Isolation**\\n\" +\n",
      "      \"2. **Reprogramming Fibroblasts to iPS Cells**\\n\" +\n",
      "      \"3. **Characterization of iPS Cells**\\n\" +\n",
      "      \"4. **Differentiation into Motor Neurons**\\n\" +\n",
      "      \"5. **Analysis of Differentiated Cells**\",\n",
      "    speakerNotes: \"This slide outlines the experimental approach taken in our study. The process begins with selecting patients and isolating fibroblasts. Next, these fibroblasts are reprogrammed into induced pluripotent stem cells (iPSCs). After characterizing these iPSCs, we differentiate them into motor neurons and perform analysis on the differentiated cells.\",\n",
      "    _meta: {\n",
      "      usage: {\n",
      "        prompt_tokens: 171,\n",
      "        completion_tokens: 155,\n",
      "        total_tokens: 326,\n",
      "        prompt_tokens_details: { cached_tokens: 0 },\n",
      "        completion_tokens_details: { reasoning_tokens: 0 }\n",
      "      }\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    title: \"Experimental Approach of the Study\",\n",
      "    markdownContent: \"1. **Isolation of Fibroblasts**: Fibroblasts were isolated from skin biopsies of elderly ALS patients.\\n\" +\n",
      "      \"2. **Reprogramming**: These fibroblasts were reprogrammed into iPS cells using defined transcription factors.\\n\" +\n",
      "      \"3. **Characterization**: The resulting iPS cells were characterized to confirm pluripotency.\\n\" +\n",
      "      \"4. **Differentiation**: iPS cells were directed to differentiate into motor neurons.\\n\" +\n",
      "      \"5. **Analysis**: The differentiated cells were analyzed to assess their identity and functionality.\",\n",
      "    speakerNotes: \"This slide outlines the key steps involved in the experimental approach of the study, detailing how fibroblasts were isolated, reprogrammed, characterized, differentiated, and analyzed.\",\n",
      "    _meta: {\n",
      "      usage: {\n",
      "        prompt_tokens: 199,\n",
      "        completion_tokens: 162,\n",
      "        total_tokens: 361,\n",
      "        prompt_tokens_details: { cached_tokens: 0 },\n",
      "        completion_tokens_details: { reasoning_tokens: 0 }\n",
      "      }\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    title: \"Methods: Patient Selection\",\n",
      "    markdownContent: \"## Participants:\\n\" +\n",
      "      \"- Two elderly female siblings (A29 and A30)\\n\" +\n",
      "      \"- Ages 82 and 89\\n\" +\n",
      "      \"- Both heterozygous for SOD1 L144F mutation\\n\" +\n",
      "      \"\\n\" +\n",
      "      \"## Clinical Presentation:\\n\" +\n",
      "      \"- A29: Diagnosed with ALS\\n\" +\n",
      "      \"- A30: Asymptomatic but signs of upper motor neuron disease\",\n",
      "    speakerNotes: \"This slide outlines the methods used for patient selection in the study. It describes the participants involved, specifically two elderly female siblings, and provides details on their ages and genetic mutation status. Additionally, it presents the clinical presentation of each participant, highlighting their diagnoses and symptoms.\",\n",
      "    _meta: {\n",
      "      usage: {\n",
      "        prompt_tokens: 190,\n",
      "        completion_tokens: 138,\n",
      "        total_tokens: 328,\n",
      "        prompt_tokens_details: { cached_tokens: 0 },\n",
      "        completion_tokens_details: { reasoning_tokens: 0 }\n",
      "      }\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    title: \"Study of ALS Patients with SOD1 L144F Mutation\",\n",
      "    markdownContent: \"## Summary of Patients\\n\" +\n",
      "      \"- **Patients**: A29 and A30 (sisters)\\n\" +\n",
      "      \"- **Ages**: 82 (A29), 89 (A30)\\n\" +\n",
      "      \"- **Mutation**: SOD1 L144F (associated with familial ALS)\\n\" +\n",
      "      \"\\n\" +\n",
      "      \"## Patient Conditions\\n\" +\n",
      "      \"- **Patient A29**: Clear clinical manifestations of ALS.\\n\" +\n",
      "      \"- **Patient A30**: Asymptomatic but shows signs of upper motor neuron disease upon examination.\\n\" +\n",
      "      \"\\n\" +\n",
      "      \"## Purpose of Study\\n\" +\n",
      "      \"To study iPS cell generation from individuals with a lifetime of exposure to the disease-causing mutation.\",\n",
      "    speakerNotes: \"Under approved protocols, the researchers recruited two elderly sisters, referred to as patients A29 and A30, aged 82 and 89, respectively. Both carried the rare SOD1 L144F mutation associated with familial ALS. Patient A29 had clear clinical manifestations of ALS, while A30 was asymptomatic but exhibited signs of upper motor neuron disease upon examination. These patients provided an opportunity to study iPS cell generation from individuals with a lifetime of exposure to the disease-causing mutation.\",\n",
      "    _meta: {\n",
      "      usage: {\n",
      "        prompt_tokens: 212,\n",
      "        completion_tokens: 245,\n",
      "        total_tokens: 457,\n",
      "        prompt_tokens_details: { cached_tokens: 0 },\n",
      "        completion_tokens_details: { reasoning_tokens: 0 }\n",
      "      }\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    title: \"Methods: Fibroblast Reprogramming\",\n",
      "    markdownContent: \"## Fibroblast Culture:\\n\" +\n",
      "      \"- Skin biopsies obtained and fibroblasts cultured\\n\" +\n",
      "      \"\\n\" +\n",
      "      \"## Reprogramming Factors:\\n\" +\n",
      "      \"- Retroviral transduction with KLF4, SOX2, OCT4, c-MYC\\n\" +\n",
      "      \"\\n\" +\n",
      "      \"## Culture Conditions:\\n\" +\n",
      "      \"- Cells placed on mouse embryonic fibroblast feeders\\n\" +\n",
      "      \"- Transitioned to embryonic stem cell medium\",\n",
      "    speakerNotes: \"This slide outlines the methods used for fibroblast reprogramming. It details the process of fibroblast culture, the reprogramming factors utilized, and the specific culture conditions necessary for successful reprogramming.\",\n",
      "    _meta: {\n",
      "      usage: {\n",
      "        prompt_tokens: 198,\n",
      "        completion_tokens: 134,\n",
      "        total_tokens: 332,\n",
      "        prompt_tokens_details: { cached_tokens: 0 },\n",
      "        completion_tokens_details: { reasoning_tokens: 0 }\n",
      "      }\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    title: \"Isolation and Reprogramming of Fibroblasts\",\n",
      "    markdownContent: \"- Fibroblasts were isolated from skin biopsies of patients and cultured in vitro.\\n\" +\n",
      "      \"- Reprogramming was done using retroviral vectors encoding four transcription factors:\\n\" +\n",
      "      \"  - KLF4\\n\" +\n",
      "      \"  - SOX2\\n\" +\n",
      "      \"  - OCT4\\n\" +\n",
      "      \"  - c-MYC\\n\" +\n",
      "      \"- These factors are known to induce pluripotency.\\n\" +\n",
      "      \"- The transduced cells were cultured on a feeder layer of mouse embryonic fibroblasts in conditions supportive of embryonic stem cells to promote reprogramming.\",\n",
      "    speakerNotes: \"Fibroblasts were isolated from skin biopsies of the patients and cultured in vitro. The fibroblasts were then reprogrammed using retroviral vectors encoding four transcription factors: KLF4, SOX2, OCT4, and c-MYC. These factors are known to induce pluripotency. The transduced cells were cultured on a feeder layer of mouse embryonic fibroblasts in conditions supportive of embryonic stem cells to promote reprogramming.\",\n",
      "    _meta: {\n",
      "      usage: {\n",
      "        prompt_tokens: 207,\n",
      "        completion_tokens: 216,\n",
      "        total_tokens: 423,\n",
      "        prompt_tokens_details: { cached_tokens: 0 },\n",
      "        completion_tokens_details: { reasoning_tokens: 0 }\n",
      "      }\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    title: \"Methods: Characterization of iPS Cells\",\n",
      "    markdownContent: \"## Verification of Reprogramming:\\n\" +\n",
      "      \"- Morphological assessment\\n\" +\n",
      "      \"- Alkaline phosphatase activity\\n\" +\n",
      "      \"\\n\" +\n",
      "      \"## Genetic Analysis:\\n\" +\n",
      "      \"- DNA fingerprinting for patient identity\\n\" +\n",
      "      \"- Sequencing for SOD1 mutation\\n\" +\n",
      "      \"\\n\" +\n",
      "      \"## Pluripotency Markers:\\n\" +\n",
      "      \"- Expression of SSEA-3, SSEA-4, TRA-1-60, TRA-1-81, NANOG\\n\" +\n",
      "      \"\\n\" +\n",
      "      \"## Karyotyping:\\n\" +\n",
      "      \"- Confirm normal chromosomal structure\",\n",
      "    speakerNotes: \"This slide outlines the methods used to characterize induced pluripotent stem cells (iPS cells). We start with the verification of reprogramming, focusing on morphological assessments and alkaline phosphatase activity. Next, we carry out genetic analysis, which includes DNA fingerprinting to confirm patient identity and sequencing to check for SOD1 mutations. We also look at the expression of pluripotency markers such as SSEA-3, SSEA-4, TRA-1-60, TRA-1-81, and NANOG. Finally, karyotyping is performed to ensure normal chromosomal structure.\",\n",
      "    _meta: {\n",
      "      usage: {\n",
      "        prompt_tokens: 224,\n",
      "        completion_tokens: 236,\n",
      "        total_tokens: 460,\n",
      "        prompt_tokens_details: { cached_tokens: 0 },\n",
      "        completion_tokens_details: { reasoning_tokens: 0 }\n",
      "      }\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    title: \"Confirmation of Successful Reprogramming\",\n",
      "    markdownContent: \"- Researchers performed several analyses to confirm successful reprogramming.\\n\" +\n",
      "      \"- Assessed colony morphology and alkaline phosphatase activity (a marker of pluripotency).\\n\" +\n",
      "      \"- Genetic analysis (DNA fingerprinting and sequencing) verified iPS cells matched patient fibroblasts and carried the SOD1 mutation.\\n\" +\n",
      "      \"- Evaluated expression of pluripotency markers:\\n\" +\n",
      "      \"  - SSEA-3\\n\" +\n",
      "      \"  - SSEA-4\\n\" +\n",
      "      \"  - TRA-1-60\\n\" +\n",
      "      \"  - TRA-1-81\\n\" +\n",
      "      \"  - NANOG through immunostaining.\\n\" +\n",
      "      \"- Confirmed normal karyotypes to verify chromosomal integrity of iPS cells.\",\n",
      "    speakerNotes: \"To confirm successful reprogramming, the researchers performed several analyses. They assessed colony morphology and alkaline phosphatase activity, a marker of pluripotency. Genetic analysis, including DNA fingerprinting and sequencing, verified that the iPS cells matched the patient fibroblasts and carried the SOD1 mutation. The expression of pluripotency markers such as SSEA-3, SSEA-4, TRA-1-60, TRA-1-81, and NANOG was evaluated through immunostaining. Normal karyotypes confirmed the chromosomal integrity of the iPS cells.\",\n",
      "    _meta: {\n",
      "      usage: {\n",
      "        prompt_tokens: 231,\n",
      "        completion_tokens: 263,\n",
      "        total_tokens: 494,\n",
      "        prompt_tokens_details: { cached_tokens: 0 },\n",
      "        completion_tokens_details: { reasoning_tokens: 0 }\n",
      "      }\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    title: \"Results: Generation of iPS Cells\",\n",
      "    markdownContent: \"- **Successful Reprogramming:**\\n\" +\n",
      "      \"  - Established stable iPS cell lines from patient A29\\n\" +\n",
      "      \"- **Patient Identity Confirmed:**\\n\" +\n",
      "      \"  - DNA fingerprinting matched donor fibroblasts\\n\" +\n",
      "      \"  - SOD1 mutation present in iPS cells\\n\" +\n",
      "      \"- **Silencing of Retroviral Transgenes:**\\n\" +\n",
      "      \"  - Endogenous pluripotency genes activated\\n\" +\n",
      "      \"  - Partial silencing of viral transgenes\",\n",
      "    speakerNotes: \"This slide presents the results of our study on the generation of induced pluripotent stem (iPS) cells. We achieved successful reprogramming, confirming the identity of the patient from whom these cells were derived. Additionally, we observed key changes in the expression of transgenes, reflecting the activation of endogenous pluripotency genes.\",\n",
      "    _meta: {\n",
      "      usage: {\n",
      "        prompt_tokens: 201,\n",
      "        completion_tokens: 170,\n",
      "        total_tokens: 371,\n",
      "        prompt_tokens_details: { cached_tokens: 0 },\n",
      "        completion_tokens_details: { reasoning_tokens: 0 }\n",
      "      }\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    title: \"iPS Cell Line Generation from Patient A29\",\n",
      "    markdownContent: \"The researchers successfully generated iPS cell lines from patient A29. DNA fingerprinting confirmed that these iPS cells were genetically identical to the donor fibroblasts. Sequencing demonstrated that the iPS cells carried the SOD1 L144F mutation. Importantly, the iPS cells activated endogenous pluripotency genes, and retroviral transgenes were partially silenced, indicating successful reprogramming.\",\n",
      "    speakerNotes: \"The research highlights the successful generation of iPS cells from patient A29, confirming their genetic identity with donor fibroblasts, the presence of a specific mutation, and evidence of successful reprogramming.\",\n",
      "    _meta: {\n",
      "      usage: {\n",
      "        prompt_tokens: 194,\n",
      "        completion_tokens: 140,\n",
      "        total_tokens: 334,\n",
      "        prompt_tokens_details: { cached_tokens: 0 },\n",
      "        completion_tokens_details: { reasoning_tokens: 0 }\n",
      "      }\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    title: \"Results: Characterization of iPS Cells\",\n",
      "    markdownContent: \"## Results: Characterization of iPS Cells\\n\" +\n",
      "      \"\\n\" +\n",
      "      \"- **Pluripotency Gene Expression:**\\n\" +\n",
      "      \"  - REX1, FOXD3, TERT, NANOG, CRIPTO expressed\\n\" +\n",
      "      \"- **Embryoid Body Formation:**\\n\" +\n",
      "      \"  - iPS cells formed embryoid bodies in suspension culture\\n\" +\n",
      "      \"- **Differentiation Potential:**\\n\" +\n",
      "      \"  - Cells differentiated into all three germ layers:\\n\" +\n",
      "      \"    - Ectoderm: β-tubulin III-positive neurons\\n\" +\n",
      "      \"    - Mesoderm: Desmin-positive muscle cells\\n\" +\n",
      "      \"    - Endoderm: α-fetoprotein-positive cells\",\n",
      "    speakerNotes: \"This slide presents the results of characterizing induced pluripotent stem (iPS) cells. We assessed three main aspects: pluripotency gene expression, embryoid body formation, and differentiation potential into the three germ layers.\",\n",
      "    _meta: {\n",
      "      usage: {\n",
      "        prompt_tokens: 231,\n",
      "        completion_tokens: 191,\n",
      "        total_tokens: 422,\n",
      "        prompt_tokens_details: { cached_tokens: 0 },\n",
      "        completion_tokens_details: { reasoning_tokens: 0 }\n",
      "      }\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    title: \"Key Findings on iPS Cells\",\n",
      "    markdownContent: \"- Quantitative RT-PCR showed iPS cells express key pluripotency genes at levels comparable to human embryonic stem cells.\\n\" +\n",
      "      \"- When cultured in suspension, iPS cells formed embryoid bodies characteristic of pluripotent cells.\\n\" +\n",
      "      \"- Upon differentiation, iPS cells gave rise to cell types from all three germ layers:  \\n\" +\n",
      "      \"  - Ectodermal neurons  \\n\" +\n",
      "      \"  - Mesodermal muscle cells  \\n\" +\n",
      "      \"  - Endodermal cells\\n\" +\n",
      "      \"- This demonstrates the pluripotency and differentiation potential of patient-specific iPS cells.\",\n",
      "    speakerNotes: \"Quantitative RT-PCR showed that the iPS cells expressed key pluripotency genes at levels comparable to human embryonic stem cells. When cultured in suspension, the iPS cells formed embryoid bodies, which is characteristic of pluripotent cells. Upon differentiation, the iPS cells gave rise to cell types representative of all three germ layers: ectodermal neurons, mesodermal muscle cells, and endodermal cells. This demonstrated the pluripotency and differentiation potential of the patient-specific iPS cells.\",\n",
      "    _meta: {\n",
      "      usage: {\n",
      "        prompt_tokens: 219,\n",
      "        completion_tokens: 237,\n",
      "        total_tokens: 456,\n",
      "        prompt_tokens_details: { cached_tokens: 0 },\n",
      "        completion_tokens_details: { reasoning_tokens: 0 }\n",
      "      }\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    title: \"Results: Differentiation into Motor Neurons\",\n",
      "    markdownContent: \"## Results: Differentiation into Motor Neurons\\n\" +\n",
      "      \"\\n\" +\n",
      "      \"- **Directed Differentiation Protocol:**\\n\" +\n",
      "      \"  - Treatment with retinoic acid and sonic hedgehog agonist\\n\" +\n",
      "      \"- **Motor Neuron Markers:**\\n\" +\n",
      "      \"  - HB9, ISLET 1/2 expression confirmed\\n\" +\n",
      "      \"  - Choline acetyltransferase (ChAT) expression\\n\" +\n",
      "      \"- **Glial Cells:**\\n\" +\n",
      "      \"  - Presence of GFAP and S100-positive glia\",\n",
      "    speakerNotes: \"This slide presents the results of our experiment on differentiating cells into motor neurons. We employed a directed differentiation protocol using retinoic acid and sonic hedgehog agonist. The markers indicating successful differentiation include HB9 and ISLET 1/2, along with choline acetyltransferase (ChAT). Additionally, we observed the presence of glial cells marked by GFAP and S100.\",\n",
      "    _meta: {\n",
      "      usage: {\n",
      "        prompt_tokens: 202,\n",
      "        completion_tokens: 198,\n",
      "        total_tokens: 400,\n",
      "        prompt_tokens_details: { cached_tokens: 0 },\n",
      "        completion_tokens_details: { reasoning_tokens: 0 }\n",
      "      }\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    title: \"Differentiation of iPS Cells into Motor Neurons\",\n",
      "    markdownContent: \"- iPS cells were directed to differentiate into motor neurons using:\\n\" +\n",
      "      \"  - Retinoic acid\\n\" +\n",
      "      \"  - Sonic hedgehog agonist\\n\" +\n",
      "      \"- Immunostaining results:\\n\" +\n",
      "      \"  - Differentiated cells expressed motor neuron-specific markers:\\n\" +\n",
      "      \"    - HB9\\n\" +\n",
      "      \"    - ISLET 1/2\\n\" +\n",
      "      \"  - Significant proportion expressed ChAT (indicative of mature cholinergic neurons)\\n\" +\n",
      "      \"- Cultures contained glial cells positive for:\\n\" +\n",
      "      \"  - GFAP\\n\" +\n",
      "      \"  - S100\\n\" +\n",
      "      \"\\n\" +\n",
      "      \"*Important for studying ALS pathology.*\",\n",
      "    speakerNotes: \"The iPS cells were directed to differentiate into motor neurons using a protocol involving retinoic acid and a sonic hedgehog agonist. Immunostaining revealed that differentiated cells expressed motor neuron-specific markers such as HB9 and ISLET 1/2. Additionally, a significant proportion of these cells expressed ChAT, an enzyme indicative of mature cholinergic neurons. The cultures also contained glial cells positive for GFAP and S100, which are important for studying ALS pathology.\",\n",
      "    _meta: {\n",
      "      usage: {\n",
      "        prompt_tokens: 211,\n",
      "        completion_tokens: 231,\n",
      "        total_tokens: 442,\n",
      "        prompt_tokens_details: { cached_tokens: 0 },\n",
      "        completion_tokens_details: { reasoning_tokens: 0 }\n",
      "      }\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    title: \"Discussion: Significance of Findings\",\n",
      "    markdownContent: \"## Key Findings\\n\" +\n",
      "      \"\\n\" +\n",
      "      \"- **Demonstrated Feasibility:**\\n\" +\n",
      "      \"  - First generation of iPS cells from elderly patients with chronic disease\\n\" +\n",
      "      \"- **Patient-Specific Disease Modeling:**\\n\" +\n",
      "      \"  - Potential to study ALS in relevant human cell types\\n\" +\n",
      "      \"- **Advancement in Stem Cell Research:**\\n\" +\n",
      "      \"  - Overcame previous technical obstacles in reprogramming\",\n",
      "    speakerNotes: \"This slide discusses the significance of our findings. We have demonstrated the feasibility of creating iPS cells from elderly patients, which is groundbreaking. Additionally, it offers a novel approach to modeling diseases, particularly ALS, using relevant human cell types. Lastly, the advancements made in stem cell research show how we have overcome several technical challenges, paving the way for future research.\",\n",
      "    _meta: {\n",
      "      usage: {\n",
      "        prompt_tokens: 185,\n",
      "        completion_tokens: 165,\n",
      "        total_tokens: 350,\n",
      "        prompt_tokens_details: { cached_tokens: 0 },\n",
      "        completion_tokens_details: { reasoning_tokens: 0 }\n",
      "      }\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    title: \"Significance of the Study\",\n",
      "    markdownContent: \"This study demonstrates the feasibility of generating iPS cells from elderly patients with a chronic neurodegenerative disease. It provides a proof-of-concept that patient-specific iPS cells can be used to produce the cell types affected in ALS, namely motor neurons and glia. This advances stem cell research by overcoming previous technical hurdles and opens new avenues for disease modeling and therapeutic development.\",\n",
      "    speakerNotes: \"This study is significant because it demonstrates the feasibility of generating iPS cells from elderly patients with a chronic neurodegenerative disease. It provides a proof-of-concept that patient-specific iPS cells can be used to produce the cell types affected in ALS, namely motor neurons and glia. This advances stem cell research by overcoming previous technical hurdles and opens new avenues for disease modeling and therapeutic development.\",\n",
      "    _meta: {\n",
      "      usage: {\n",
      "        prompt_tokens: 192,\n",
      "        completion_tokens: 168,\n",
      "        total_tokens: 360,\n",
      "        prompt_tokens_details: { cached_tokens: 0 },\n",
      "        completion_tokens_details: { reasoning_tokens: 0 }\n",
      "      }\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    title: \"Discussion: Limitations and Challenges\",\n",
      "    markdownContent: \"- **Retroviral Integration:**  \\n\" +\n",
      "      \"  - Potential genetic and insertional mutagenesis risks  \\n\" +\n",
      "      \"- **Partial Transgene Silencing:**  \\n\" +\n",
      "      \"  - Some viral transgenes remained active  \\n\" +\n",
      "      \"- **Functional Maturity:**  \\n\" +\n",
      "      \"  - Further studies needed to assess physiological functionality of neurons\",\n",
      "    speakerNotes: \"In this slide, we address the key limitations and challenges faced in our study. We highlight the risks associated with retroviral integration, particularly in relation to genetic and insertional mutagenesis. Additionally, we discuss the issue of partial transgene silencing, where some viral transgenes continue to remain active. Finally, we emphasize the need for further studies to assess the physiological functionality of the neurons, as determining functional maturity is crucial for the long-term implications of our research.\",\n",
      "    _meta: {\n",
      "      usage: {\n",
      "        prompt_tokens: 173,\n",
      "        completion_tokens: 177,\n",
      "        total_tokens: 350,\n",
      "        prompt_tokens_details: { cached_tokens: 0 },\n",
      "        completion_tokens_details: { reasoning_tokens: 0 }\n",
      "      }\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    title: \"Limitations of Retroviral Vectors in Research\",\n",
      "    markdownContent: \"- Risks of insertional mutagenesis with retroviral vectors.\\n\" +\n",
      "      \"- Not all retroviral transgenes were fully silenced, potentially affecting cell behavior.\\n\" +\n",
      "      \"- While cells express markers of motor neurons, further work is required to confirm functional maturity.\\n\" +\n",
      "      \"- Additional research needed for suitability in disease modeling or therapeutic applications.\",\n",
      "    speakerNotes: \"Despite the promising results, there are limitations to consider. The use of retroviral vectors poses risks due to potential insertional mutagenesis. Not all retroviral transgenes were fully silenced, which could affect cell behavior. Additionally, while the cells expressed markers of motor neurons, further work is needed to confirm their functional maturity and suitability for disease modeling or therapeutic applications.\",\n",
      "    _meta: {\n",
      "      usage: {\n",
      "        prompt_tokens: 188,\n",
      "        completion_tokens: 158,\n",
      "        total_tokens: 346,\n",
      "        prompt_tokens_details: { cached_tokens: 0 },\n",
      "        completion_tokens_details: { reasoning_tokens: 0 }\n",
      "      }\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    title: \"Conclusion: Key Findings\",\n",
      "    markdownContent: \"- **iPS Cells Generated from ALS Patients:**\\n\" +\n",
      "      \"  - Successful reprogramming of fibroblasts from elderly ALS patients\\n\" +\n",
      "      \"- **Differentiation into Relevant Cell Types:**\\n\" +\n",
      "      \"  - iPS cells differentiated into motor neurons and glia\\n\" +\n",
      "      \"- **Potential Applications:**\\n\" +\n",
      "      \"  - Disease modeling\\n\" +\n",
      "      \"  - Drug screening\\n\" +\n",
      "      \"  - Foundations for cell replacement therapies\",\n",
      "    speakerNotes: \"This slide summarizes the key findings related to induced pluripotent stem (iPS) cells generated from ALS patients. It highlights the successful reprogramming process, the differentiation capabilities into motor neurons and glia, and the various potential applications such as disease modeling, drug screening, and foundational work for future cell replacement therapies.\",\n",
      "    _meta: {\n",
      "      usage: {\n",
      "        prompt_tokens: 189,\n",
      "        completion_tokens: 156,\n",
      "        total_tokens: 345,\n",
      "        prompt_tokens_details: { cached_tokens: 0 },\n",
      "        completion_tokens_details: { reasoning_tokens: 0 }\n",
      "      }\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    title: \"Conclusion\",\n",
      "    markdownContent: \"In conclusion, the study successfully generated patient-specific iPS cells from elderly individuals with ALS and differentiated them into motor neurons and glia. These findings have significant implications for ALS research, offering new tools for disease modeling and drug discovery. This work lays the groundwork for potential future therapies involving patient-specific cell replacement.\",\n",
      "    speakerNotes: \"In conclusion, the study successfully generated patient-specific iPS cells from elderly individuals with ALS and differentiated them into motor neurons and glia. These findings have significant implications for ALS research, offering new tools for disease modeling and drug discovery. This work lays the groundwork for potential future therapies involving patient-specific cell replacement.\",\n",
      "    _meta: {\n",
      "      usage: {\n",
      "        prompt_tokens: 175,\n",
      "        completion_tokens: 134,\n",
      "        total_tokens: 309,\n",
      "        prompt_tokens_details: { cached_tokens: 0 },\n",
      "        completion_tokens_details: { reasoning_tokens: 0 }\n",
      "      }\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    title: \"Future Directions: Disease Modeling\",\n",
      "    markdownContent: \"## Modeling ALS Pathogenesis:\\n\" +\n",
      "      \"- Study disease mechanisms in patient-derived neurons\\n\" +\n",
      "      \"\\n\" +\n",
      "      \"## Genetic Studies:\\n\" +\n",
      "      \"- Investigate effects of SOD1 mutation at cellular level\\n\" +\n",
      "      \"\\n\" +\n",
      "      \"## Comparative Analysis:\\n\" +\n",
      "      \"- Compare iPS-derived neurons from affected and unaffected individuals\",\n",
      "    speakerNotes: \"In this slide, we outline the future directions in disease modeling, particularly for ALS. We highlight three major areas: First, we will focus on modeling ALS pathogenesis by studying disease mechanisms in patient-derived neurons. Second, for genetic studies, we will investigate the effects of the SOD1 mutation at the cellular level. Lastly, we will conduct a comparative analysis of iPS-derived neurons from both affected and unaffected individuals to better understand the disease.\",\n",
      "    _meta: {\n",
      "      usage: {\n",
      "        prompt_tokens: 176,\n",
      "        completion_tokens: 158,\n",
      "        total_tokens: 334,\n",
      "        prompt_tokens_details: { cached_tokens: 0 },\n",
      "        completion_tokens_details: { reasoning_tokens: 0 }\n",
      "      }\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    title: \"Future Research on ALS Pathogenesis\",\n",
      "    markdownContent: \"- Focus on patient-specific iPS cells to model ALS pathogenesis\\n\" +\n",
      "      \"- Study neurons derived from SOD1 mutation patients \\n\" +\n",
      "      \"- Investigate effects of genetic alteration on cellular function \\n\" +\n",
      "      \"- Comparative studies between affected and unaffected individuals \\n\" +\n",
      "      \"- Aim to understand disease mechanisms and identify therapeutic targets\",\n",
      "    speakerNotes: \"Future research will focus on using these patient-specific iPS cells to model ALS pathogenesis. By studying neurons derived from patients carrying the SOD1 mutation, researchers can investigate how this genetic alteration affects cellular function. Comparative studies between neurons from affected and unaffected individuals could shed light on disease mechanisms and identify potential therapeutic targets.\",\n",
      "    _meta: {\n",
      "      usage: {\n",
      "        prompt_tokens: 177,\n",
      "        completion_tokens: 139,\n",
      "        total_tokens: 316,\n",
      "        prompt_tokens_details: { cached_tokens: 0 },\n",
      "        completion_tokens_details: { reasoning_tokens: 0 }\n",
      "      }\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    title: \"Future Directions: Drug Screening\",\n",
      "    markdownContent: \"## High-Throughput Screening:\\n\" +\n",
      "      \"- Test compounds on patient-derived motor neurons\\n\" +\n",
      "      \"\\n\" +\n",
      "      \"## Identify Therapeutic Agents:\\n\" +\n",
      "      \"- Discover drugs that improve neuron survival or function\\n\" +\n",
      "      \"\\n\" +\n",
      "      \"## Personalized Medicine:\\n\" +\n",
      "      \"- Tailor treatments based on patient-specific cellular responses\",\n",
      "    speakerNotes: \"This slide focuses on the future directions in drug screening, highlighting three key areas: High-Throughput Screening, Identifying Therapeutic Agents, and Personalized Medicine. Each area emphasizes the importance of innovative approaches to enhance drug discovery and treatment strategies that are more effective and tailored to individual patient needs.\",\n",
      "    _meta: {\n",
      "      usage: {\n",
      "        prompt_tokens: 173,\n",
      "        completion_tokens: 126,\n",
      "        total_tokens: 299,\n",
      "        prompt_tokens_details: { cached_tokens: 0 },\n",
      "        completion_tokens_details: { reasoning_tokens: 0 }\n",
      "      }\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    title: \"Future Direction in Drug Screening\",\n",
      "    markdownContent: \"- Utilize patient-specific motor neurons for drug screening.\\n\" +\n",
      "      \"- Implement high-throughput assays to test numerous compounds.\\n\" +\n",
      "      \"- Identify compounds that enhance neuron survival or mitigate disease phenotypes.\\n\" +\n",
      "      \"- Potential for discovering new therapeutic agents.\\n\" +\n",
      "      \"- Advancing personalized medicine by tailoring treatments based on cellular responses.\",\n",
      "    speakerNotes: \"Another future direction is utilizing patient-specific motor neurons for drug screening. High-throughput assays can test numerous compounds to identify those that enhance neuron survival or mitigate disease phenotypes. This approach holds promise for discovering new therapeutic agents and advancing personalized medicine by tailoring treatments to individual patients based on their cellular responses.\",\n",
      "    _meta: {\n",
      "      usage: {\n",
      "        prompt_tokens: 173,\n",
      "        completion_tokens: 134,\n",
      "        total_tokens: 307,\n",
      "        prompt_tokens_details: { cached_tokens: 0 },\n",
      "        completion_tokens_details: { reasoning_tokens: 0 }\n",
      "      }\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    title: \"Future Directions: Cell Replacement Therapies\",\n",
      "    markdownContent: \"## Regenerative Medicine Potential:\\n\" +\n",
      "      \"- Develop strategies for replacing lost motor neurons\\n\" +\n",
      "      \"\\n\" +\n",
      "      \"## Overcoming Current Limitations:\\n\" +\n",
      "      \"- Address challenges with iPS cell safety and integration\\n\" +\n",
      "      \"\\n\" +\n",
      "      \"## Long-Term Goals:\\n\" +\n",
      "      \"- Translate findings into clinical applications for ALS patients\",\n",
      "    speakerNotes: \"This slide discusses the future directions in cell replacement therapies, particularly focusing on regenerative medicine. We highlight the potential to develop strategies for replacing lost motor neurons, the need to overcome current limitations related to induced pluripotent stem (iPS) cells, and the long-term goals of translating these findings into clinical applications for patients with ALS.\",\n",
      "    _meta: {\n",
      "      usage: {\n",
      "        prompt_tokens: 175,\n",
      "        completion_tokens: 137,\n",
      "        total_tokens: 312,\n",
      "        prompt_tokens_details: { cached_tokens: 0 },\n",
      "        completion_tokens_details: { reasoning_tokens: 0 }\n",
      "      }\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    title: \"Exploring Cell Replacement Therapies\",\n",
      "    markdownContent: \"- Ultimate goal: explore cell replacement therapies  \\n\" +\n",
      "      \"- Develop methods for safe transplantation of patient-specific motor neurons  \\n\" +\n",
      "      \"- Potentially restore lost functions  \\n\" +\n",
      "      \"- Overcome limitations:  \\n\" +\n",
      "      \"  - Ensure safety of iPS cells  \\n\" +\n",
      "      \"  - Ensure proper integration  \\n\" +\n",
      "      \"- Translate laboratory findings into clinical benefits for ALS patients\",\n",
      "    speakerNotes: \"Lastly, the ultimate goal is to explore cell replacement therapies. Developing methods to safely transplant patient-specific motor neurons back into patients could potentially restore lost functions. Overcoming current limitations, such as ensuring the safety of iPS cells and their proper integration, is crucial. These efforts aim to translate laboratory findings into tangible clinical benefits for ALS patients in the future.\",\n",
      "    _meta: {\n",
      "      usage: {\n",
      "        prompt_tokens: 184,\n",
      "        completion_tokens: 159,\n",
      "        total_tokens: 343,\n",
      "        prompt_tokens_details: { cached_tokens: 0 },\n",
      "        completion_tokens_details: { reasoning_tokens: 0 }\n",
      "      }\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    title: \"Closing Remarks\",\n",
      "    markdownContent: \"### Transformative Impact:\\n\" +\n",
      "      \"- Study represents a significant step in stem cell and ALS research\\n\" +\n",
      "      \"\\n\" +\n",
      "      \"### Collaboration:\\n\" +\n",
      "      \"- Highlights importance of interdisciplinary efforts\\n\" +\n",
      "      \"\\n\" +\n",
      "      \"### Acknowledgements:\\n\" +\n",
      "      \"- Credit to the researchers and participants who made the study possible\",\n",
      "    speakerNotes: \"In concluding our presentation, we want to emphasize the transformative impact of our study on stem cell and ALS research, the critical role of collaboration in our success, and acknowledge the contributions of all researchers and participants involved.\",\n",
      "    _meta: {\n",
      "      usage: {\n",
      "        prompt_tokens: 168,\n",
      "        completion_tokens: 106,\n",
      "        total_tokens: 274,\n",
      "        prompt_tokens_details: { cached_tokens: 0 },\n",
      "        completion_tokens_details: { reasoning_tokens: 0 }\n",
      "      }\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    title: \"Closing Remarks on Stem Cell Technology and ALS Research\",\n",
      "    markdownContent: \"In closing, this study represents a transformative advancement in both stem cell technology and ALS research. It highlights the potential of patient-specific iPS cells to revolutionize our understanding and treatment of neurodegenerative diseases. The success of this research underscores the importance of collaboration across disciplines and institutions. We owe gratitude to the dedicated researchers and the patients who generously contributed to this landmark study.\",\n",
      "    speakerNotes: \"In this slide, we emphasize the importance of the research findings, the collaborative efforts behind them, and express gratitude to those involved.\",\n",
      "    _meta: {\n",
      "      usage: {\n",
      "        prompt_tokens: 188,\n",
      "        completion_tokens: 120,\n",
      "        total_tokens: 308,\n",
      "        prompt_tokens_details: { cached_tokens: 0 },\n",
      "        completion_tokens_details: { reasoning_tokens: 0 }\n",
      "      }\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    title: \"References\",\n",
      "    markdownContent: \"- **Dimos, J.T., et al. (2008).** Induced Pluripotent Stem Cells Generated from Patients with ALS Can Be Differentiated into Motor Neurons. _Science_, 321(5893), 1218-1221.\",\n",
      "    speakerNotes: \"This slide includes a reference to a significant study by Dimos et al. that discusses the generation of induced pluripotent stem cells from ALS patients and their differentiation into motor neurons.\",\n",
      "    _meta: {\n",
      "      usage: {\n",
      "        prompt_tokens: 167,\n",
      "        completion_tokens: 103,\n",
      "        total_tokens: 270,\n",
      "        prompt_tokens_details: { cached_tokens: 0 },\n",
      "        completion_tokens_details: { reasoning_tokens: 0 }\n",
      "      }\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    title: \"Speaker Notes\",\n",
      "    markdownContent: \"For those interested in exploring this study further, I encourage you to read the full paper published in _Science_ by Dimos and colleagues in 2008. Thank you for your attention, and I'm happy to discuss any questions you may have.\",\n",
      "    speakerNotes: \"\",\n",
      "    _meta: {\n",
      "      usage: {\n",
      "        prompt_tokens: 163,\n",
      "        completion_tokens: 63,\n",
      "        total_tokens: 226,\n",
      "        prompt_tokens_details: { cached_tokens: 0 },\n",
      "        completion_tokens_details: { reasoning_tokens: 0 }\n",
      "      }\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    title: \"End of Presentation\",\n",
      "    markdownContent: \"# End of Presentation\",\n",
      "    speakerNotes: \"Conclude the presentation by summarizing key points and thanking the audience for their time.\",\n",
      "    _meta: {\n",
      "      usage: {\n",
      "        prompt_tokens: 114,\n",
      "        completion_tokens: 36,\n",
      "        total_tokens: 150,\n",
      "        prompt_tokens_details: { cached_tokens: 0 },\n",
      "        completion_tokens_details: { reasoning_tokens: 0 }\n",
      "      }\n",
      "    }\n",
      "  },\n",
      "  {\n",
      "    title: \"Speaker Notes\",\n",
      "    markdownContent: \"Thank you all for your time and engagement during this presentation. The development of patient-specific iPS cells represents a promising frontier in understanding and treating ALS. I look forward to any feedback or discussion points you might have.\",\n",
      "    speakerNotes: \"Thank you all for your time and engagement during this presentation. The development of patient-specific iPS cells represents a promising frontier in understanding and treating ALS. I look forward to any feedback or discussion points you might have.\",\n",
      "    _meta: {\n",
      "      usage: {\n",
      "        prompt_tokens: 157,\n",
      "        completion_tokens: 99,\n",
      "        total_tokens: 256,\n",
      "        prompt_tokens_details: { cached_tokens: 0 },\n",
      "        completion_tokens_details: { reasoning_tokens: 0 }\n",
      "      }\n",
      "    }\n",
      "  }\n",
      "]\n"
     ]
    }
   ],
   "source": [
    "console.log(processedSlides)"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Deno",
   "language": "typescript",
   "name": "deno"
  },
  "language_info": {
   "codemirror_mode": "typescript",
   "file_extension": ".ts",
   "mimetype": "text/x.typescript",
   "name": "typescript",
   "nbconvert_exporter": "script",
   "pygments_lexer": "typescript",
   "version": "5.6.2"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
